https://trial.medpath.com/news/d150494318e68376/medtronic-appoints-chad-spooner-as-cfo-for-minimed-diabetes-spinoff 2025-07-09T00:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/b72a3290cb28bbd1/adagene-partners-with-conjugatebio-to-develop-novel-bispecific-antibody-drug-conjugates 2025-07-09T00:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/4278bf580d04750a/eye-net-achieves-99-detection-rate-in-french-urban-mobility-safety-trial 2025-07-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c887a5d604001851/eluciderm-receives-fda-clearance-for-first-in-human-trial-of-elu42-in-diabetic-foot-ulcers 2025-07-08T23:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/99711ee30a34f3cf/johnson-johnson-submits-fda-application-to-expand-caplyta-for-schizophrenia-relapse-prevention 2025-07-08T21:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/ebef966b8f2bcf31/prokidney-s-rilparencel-shows-promising-phase-2-results-for-diabetic-kidney-disease 2025-07-08T21:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/e0429a0a262ab60c/iric-and-ipsen-initiate-phase-1-trial-of-raf-inhibitor-ipn01195-for-solid-tumors 2025-07-08T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/d00b10468b324e89/dermata-therapeutics-secures-australian-patent-for-needle-free-botulinum-toxin-hyperhidrosis-treatment 2025-07-08T21:19:57+00:00 hourly 0.9 https://trial.medpath.com/news/4994ceb9e54f3029/solid-biosciences-receives-fda-and-health-canada-approval-for-first-in-class-gene-therapy-targeting-fatal-heart-rhythm-disorder 2025-07-08T21:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/012eb6b6f5970e0f/georgia-tech-develops-exploding-capsule-technology-for-needle-free-insulin-delivery 2025-07-08T20:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/a5da1e7e6792b7d1/fziomed-receives-fda-de-novo-authorization-for-oxiplex-gel-in-lumbar-spine-surgery 2025-07-08T20:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/b962472b853de20b/cumulus-neuroscience-raises-ps3-25m-to-transform-neurological-clinical-trials-with-fda-cleared-eeg-technology 2025-07-08T20:20:50+00:00 hourly 0.9 https://trial.medpath.com/news/ecf1ee0eda3afadf/nyb-ai-and-pnaseer-inc-form-strategic-partnership-to-advance-ai-powered-hair-regeneration-research 2025-07-08T20:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/9303da1cfeea749e/stampede-trial-shows-metformin-improves-metabolic-health-in-metastatic-prostate-cancer-patients-despite-no-survival-benefit 2025-07-08T19:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/c4f10adc95bf052b/cardio-diagnostics-partners-with-agepha-pharma-to-validate-ai-powered-precision-medicine-approach-for-inflammation-driven-coronary-heart-disease 2025-07-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/c5075b8d7805ab79/samsung-acquires-providence-digital-health-spinoff-xealth-to-bridge-consumer-wellness-and-clinical-care 2025-07-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/d52af84788e21bbf/ciloa-secures-eur6-5-million-french-government-funding-to-advance-novel-adiponectin-based-therapy-for-obesity-and-type-2-diabetes 2025-07-08T17:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/1557726fff63e89e/viiv-healthcare-presents-real-world-data-on-long-acting-hiv-treatments-at-ias-2025 2025-07-08T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/0490734770c4c6d7/first-nanobody-treatment-shows-promise-against-deadly-nipah-and-hendra-viruses 2025-07-08T17:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/35d08b74cac0748b/nobel-peace-prize-laureate-james-orbinski-joins-ai-drug-repurposing-startup-fifty-1-labs 2025-07-08T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/56184d657878a9e5/neonc-technologies-secures-50-million-investment-to-expand-brain-cancer-clinical-trials-in-mena-region 2025-07-08T17:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/50598f363283deee/bostongene-partners-with-swog-cancer-research-network-for-ai-driven-small-cell-lung-cancer-precision-medicine-trial 2025-07-08T17:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/28c53cb615f95b71/amarna-therapeutics-and-northx-biologics-advance-gene-therapy-for-type-1-diabetes-toward-clinical-trials 2025-07-08T17:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/584bef3d1f1574c9/concentra-biosciences-acquires-cargo-therapeutics-for-202m-following-car-t-trial-failure 2025-07-08T17:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/51002273004f4a60/champions-oncology-launches-comprehensive-radiopharmaceutical-services-platform-with-expanded-isotope-capabilities 2025-07-08T17:27:25+00:00 hourly 0.9 https://trial.medpath.com/news/ef2308de21e574be/quanterix-completes-akoya-biosciences-acquisition-creating-integrated-biomarker-detection-platform 2025-07-08T17:27:23+00:00 hourly 0.9 https://trial.medpath.com/news/3cd9881fa35ffb1f/eib-provides-eur150-million-to-alfasigma-for-rare-disease-and-specialty-care-innovation 2025-07-08T17:27:10+00:00 hourly 0.9 https://trial.medpath.com/news/55ff9fee8d9184eb/recursion-pharmaceuticals-acquires-full-rights-to-rev102-potential-first-in-class-oral-enpp1-inhibitor-for-hypophosphatasia 2025-07-08T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/3e4fbf2a29b47f2a/jcr-pharmaceuticals-licenses-just-aav-gene-therapy-platform-to-alexion-in-825-million-deal 2025-07-08T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/3c308c40e0fde3a3/certara-expands-clinical-technology-partnership-with-merck-to-streamline-data-management 2025-07-08T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/01fee25f4fdbdd75/mmj-international-advances-first-plant-based-cannabis-drug-mmj-001-for-huntington-s-disease-chorea 2025-07-08T17:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/e398afd2f5422ee8/circular-genomics-secures-250k-addf-investment-to-advance-circrna-blood-biomarkers-for-alzheimer-s-diagnosis 2025-07-08T17:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/7cb5b34c893aa4e3/hansa-biopharma-appoints-dr-richard-philipson-as-chief-medical-officer-to-lead-next-development-phase 2025-07-08T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/7c866987e14a547a/flightpath-biosciences-licenses-microbiome-sparing-antibiotic-lolamicin-for-gram-negative-bacterial-infections 2025-07-08T17:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/03442ac6adaa0379/australian-scientists-develop-proteus-biological-ai-platform-to-accelerate-drug-discovery 2025-07-08T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/6619976826f506a5/predictive-oncology-secures-10m-equity-agreement-to-advance-ai-driven-cancer-drug-discovery 2025-07-08T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/8d5d63423d537d49/taiho-s-pizuglanstat-fails-to-meet-primary-endpoint-in-phase-iii-duchenne-muscular-dystrophy-trial 2025-07-08T16:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/ac9f244d85702ae2/varmx-receives-fda-fast-track-designation-for-vmx-c001-anticoagulant-reversal-therapy 2025-07-08T16:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/f9a43a75dbcee8d4/mendaera-s-focalist-handheld-robotic-system-receives-fda-clearance-for-ultrasound-guided-procedures 2025-07-08T16:19:47+00:00 hourly 0.9 https://trial.medpath.com/news/a5b0f15960fdb379/caris-life-sciences-validates-ai-powered-blood-test-for-multi-cancer-detection-and-monitoring 2025-07-08T16:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/c9dd2c4c09185d49/insightec-receives-fda-approval-for-bilateral-focused-ultrasound-treatment-in-advanced-parkinson-s-disease 2025-07-08T16:17:09+00:00 hourly 0.9 https://trial.medpath.com/news/861fb8373b22c950/verified-clinical-trials-launches-advanced-subject-registry-platform-in-japan-to-combat-duplicate-trial-participants 2025-07-08T16:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/6da04e0c54708fe0/dual-payload-adcs-enter-clinical-testing-as-innovent-and-chengdu-kanghong-pioneer-next-generation-cancer-therapeutics 2025-07-08T16:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/2598f0a92c0875a8/anthem-biosciences-launches-3395-crore-ipo-as-contract-research-organization-targets-public-markets 2025-07-08T16:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/d13891fec607371a/simcere-submits-new-drug-application-for-rademikibart-in-china-s-70-million-patient-atopic-dermatitis-market 2025-07-08T16:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/6aef3d33630072bd/sarilumab-combination-achieves-63-6-response-rate-in-advanced-melanoma-phase-2-trial 2025-07-08T15:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/af381b2b015bb89f/covid-19-pandemic-drove-sharp-rise-in-obesity-among-black-children-and-adolescents-study-finds 2025-07-08T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e8d6801ba463c1c4/johnson-johnson-submits-fda-application-for-caplyta-schizophrenia-relapse-prevention-based-on-63-risk-reduction-data 2025-07-08T12:56:29+00:00 hourly 0.9 https://trial.medpath.com/news/b8dfa99886aa52c3/fda-authorizes-emergency-compassionate-use-of-var-200-for-ultra-rare-apocii-amyloidosis 2025-07-08T12:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/7867c7e8fafd84e3/crescent-biopharma-appoints-jan-pinkas-as-chief-scientific-officer-to-advance-oncology-pipeline 2025-07-08T12:54:56+00:00 hourly 0.9 https://trial.medpath.com/news/132728d29c3a26eb/optibrium-secures-multi-million-pound-financing-to-accelerate-ai-powered-drug-discovery-platform 2025-07-08T12:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/f88d1ad6b41bab7e/prokidney-s-rilparencel-shows-78-improvement-in-kidney-function-decline-in-phase-2-ckd-trial 2025-07-08T12:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/fddf504bfb41199a/jasper-therapeutics-briquilimab-shows-89-complete-response-rate-in-csu-despite-manufacturing-setbacks 2025-07-08T12:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/135ce6ae2ce31b75/duke-street-bio-receives-fda-fast-track-designation-for-brain-penetrating-parp1-inhibitor-dsb2455 2025-07-08T12:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/7de1d2779caf7108/veeda-lifesciences-partners-with-mango-sciences-to-deploy-ai-powered-platform-for-enhanced-clinical-trial-diversity 2025-07-08T12:19:53+00:00 hourly 0.9 https://trial.medpath.com/news/5f32039fb693b763/uspto-expands-fast-track-patent-program-to-20000-applications-annually-as-accelerated-examination-program-ends 2025-07-08T11:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/2730f9b0a4dbffa3/morphic-medical-receives-ce-mark-for-reset-obesity-device-targeting-alternative-to-bariatric-surgery 2025-07-08T10:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/82c3b59643458e8b/basilea-secures-39-million-barda-funding-to-advance-novel-antifungal-candidates-fosmanogepix-and-bal2062 2025-07-08T09:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/a891f52bce958acd/navamedic-expands-into-addiction-treatment-with-nok-225-million-acquisition-of-dne-pharma 2025-07-08T09:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/f206f61d4cffe41f/biorce-secures-eur5m-to-transform-clinical-trials-with-ai-driven-platform 2025-07-08T09:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/e1313710531305fe/lobe-sciences-secures-european-patent-protection-for-dha-based-sickle-cell-disease-treatment 2025-07-08T09:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/2ede11301b14b7ee/corbion-gains-chinese-regulatory-approval-for-algae-derived-omega-3-dha-products 2025-07-08T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/7520973ef9543f86/novartis-receives-approval-for-first-malaria-treatment-designed-for-newborns-and-young-infants 2025-07-08T08:12:23+00:00 hourly 0.9 https://trial.medpath.com/news/94c415216b264171/kras-g12c-mutations-associated-with-shorter-survival-in-first-line-metastatic-colorectal-cancer-treatment 2025-07-08T08:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/fe8718a45e1b2bed/cero-therapeutics-advances-novel-cer-t-cell-therapy-for-aml-with-invivoscribe-diagnostic-support 2025-07-08T04:54:23+00:00 hourly 0.9 https://trial.medpath.com/news/804dc4c8c63dccb9/omass-therapeutics-to-present-first-preclinical-data-for-mc2-receptor-antagonist-oms1620-at-endo-2025 2025-07-08T03:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/23dd652bf93a551b/sharp-clinical-launches-cdmo-podcast-series-to-address-drug-development-challenges 2025-07-08T03:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/f3220d01b34e8dfb/inventiva-receives-10-million-milestone-payment-from-cttq-for-mash-drug-development-partnership 2025-07-08T01:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/f6f44be45825ed3e/medmira-launches-clinical-trial-for-dual-hiv-syphilis-self-test-in-canada 2025-07-08T01:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/d117da3c89137730/abcellera-advances-two-first-in-class-antibody-therapies-to-phase-1-trials-following-strategic-pivot 2025-07-08T01:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/46efd0c71a4c8d77/ascentage-pharma-strengthens-leadership-team-with-new-cfo-and-senior-vp-appointments 2025-07-08T01:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/a34fe61c53234d76/fda-approves-first-xolair-biosimilar-omlyclo-for-allergic-diseases-marking-milestone-in-allergy-treatment-access 2025-07-08T01:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/7819e803d4e25c0f/yiv-906-shows-promising-results-in-phase-2b-trial-for-advanced-hepatocellular-carcinoma-with-hepatitis-b 2025-07-07T23:15:15+00:00 hourly 0.9 https://trial.medpath.com/news/2231564890f3d641/artelo-s-art12-11-cocrystal-shows-superior-antidepressant-effects-over-leading-ssri-in-preclinical-study 2025-07-07T22:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/064fc11fdabdd600/nanobiotix-secures-eu-regulatory-harmonization-and-new-patent-for-cancer-radioenhancer-jnj-1900 2025-07-07T21:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/2f8210235173184c/intranasal-covid-19-vaccines-show-superior-mucosal-immunity-and-long-term-protection-in-preclinical-studies 2025-07-07T21:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/491d0ae5233cea0e/insurance-disparities-widen-cancer-survival-gaps-despite-immune-checkpoint-inhibitor-advances 2025-07-07T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/c8a544853448157e/pd-l1-expression-correlates-with-hrd-status-and-predicts-survival-in-high-grade-serous-ovarian-cancer 2025-07-07T21:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/a8a962a50a8532e4/aspivix-launches-mhra-approved-carevix-cervical-stabilizer-in-uk-demonstrating-73-pain-reduction-in-iud-procedures 2025-07-07T21:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/80700f38e648cd2a/blue-lake-and-cyanvac-report-promising-phase-1-results-for-intranasal-covid-19-vaccine-cvxga 2025-07-07T20:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/9f12b38155e890e8/fda-study-reveals-liver-safety-concerns-with-low-dose-cbd-in-5-of-healthy-adults 2025-07-07T20:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/6d10e654448b0f79/venture-medical-leads-eur6-million-investment-in-cold-plasma-wound-therapy-developer-plasmacure 2025-07-07T18:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/41ab7cccc7625589/panther-therapeutics-initiates-phase-1b-trial-of-novel-localized-chemotherapy-film-for-pancreatic-cancer 2025-07-07T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/ef4600a6237d88db/italy-appoints-special-commissioner-to-fast-track-novo-nordisk-s-2-3-billion-manufacturing-investment 2025-07-07T17:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/fe95335a8b1746dd/beyondspring-s-plinabulin-shows-promise-in-reversing-checkpoint-inhibitor-resistance-through-dendritic-cell-activation 2025-07-07T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/3f075c7283f0af34/researchers-identify-key-resistance-mechanism-to-cdk4-6-inhibitors-in-hr-her2-breast-cancer 2025-07-07T16:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/3f7fcbe8be8ab2b6/corticosteroids-identified-as-major-factor-limiting-immunotherapy-effectiveness-in-lung-cancer 2025-07-07T16:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/37b6736e78dc5576/maplight-therapeutics-initiates-phase-2-trial-of-novel-m1-m4-muscarinic-agonist-ml-007c-ma-for-schizophrenia-treatment 2025-07-07T16:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/314a02188f9640ad/fujifilm-s-ff-10832-receives-fda-orphan-drug-designation-for-biliary-tract-cancer-treatment 2025-07-07T16:33:25+00:00 hourly 0.9 https://trial.medpath.com/news/bacea2dd4db2cf0e/alcon-acquires-lumithera-s-photobiomodulation-device-for-dry-amd-treatment 2025-07-07T16:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/92b27d22f0681482/pace-life-sciences-expands-salem-facility-with-new-aseptic-fill-finish-center-of-excellence 2025-07-07T16:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/167e7fb77b721f17/heartbeat-bio-and-biotx-ai-partner-to-accelerate-heart-failure-drug-discovery-using-ai-and-human-cardiac-organoids 2025-07-07T16:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/d5d841f31958aa2f/synfini-secures-8-9-million-to-accelerate-ai-driven-small-molecule-drug-discovery-platform 2025-07-07T16:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/db7f31425ac705a0/restore-medical-secures-23m-series-b-to-advance-transcatheter-heart-failure-device-following-fda-breakthrough-designation 2025-07-07T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/1e3857354c7520d1/sirtex-medical-s-sir-spheres-y-90-resin-microspheres-receive-fda-approval-for-unresectable-hepatocellular-carcinoma 2025-07-07T16:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/37a462d77ec3a032/fda-grants-orphan-drug-designation-to-mustang-bio-s-mb-101-car-t-therapy-for-brain-cancer-treatment 2025-07-07T16:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/bdbf1c38c077696e/bezuclastinib-achieves-87-response-rate-in-pivotal-trial-for-non-advanced-systemic-mastocytosis 2025-07-07T16:22:49+00:00 hourly 0.9 https://trial.medpath.com/news/4b8d078d0e0df1b5/orchard-therapeutics-completes-enrollment-in-pivotal-gene-therapy-trial-for-hurler-syndrome 2025-07-07T16:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/332d54f64c2cd186/biosapien-secures-8-million-in-extended-pre-series-a-round-for-revolutionary-cancer-treatment-platform 2025-07-07T16:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/0a0a546d56ced3c5/oncolytic-virus-immune-checkpoint-inhibitor-combinations-show-promise-in-melanoma-treatment 2025-07-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/56c765c4ce749d8c/phytogaia-s-tocotrienol-supplement-shows-promise-for-healthy-aging-in-clinical-trial 2025-07-07T15:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/81276aafef7a2603/scottish-health-authority-approves-theramex-s-abaloparatide-for-high-risk-osteoporosis-treatment 2025-07-07T13:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/2b95f91f6e1a474a/biocryst-pharmaceuticals-appoints-babar-ghias-as-cfo-and-head-of-corporate-development 2025-07-07T13:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/41791951930a6c09/pakistan-approves-chinese-biosimilar-cancer-drug-to-expand-access-to-affordable-bevacizumab-treatment 2025-07-07T13:03:23+00:00 hourly 0.9 https://trial.medpath.com/news/b802f6538ba49fc7/biosynth-opens-expanded-gmp-bioconjugation-facility-in-berlin-to-support-next-generation-therapeutics 2025-07-07T13:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/2adb15824c992373/chugai-and-gero-form-250m-partnership-to-develop-ai-driven-antibody-therapies-for-age-related-diseases 2025-07-07T13:02:16+00:00 hourly 0.9 https://trial.medpath.com/news/676ab7fe420fce31/als-community-files-citizens-petition-seeking-fda-approval-for-nurown-stem-cell-therapy 2025-07-07T13:01:18+00:00 hourly 0.9 https://trial.medpath.com/news/c928bfd705ef5c79/corflow-therapeutics-receives-fda-approval-for-moca-ii-pivotal-trial-testing-novel-heart-attack-diagnostic-technology 2025-07-07T13:00:50+00:00 hourly 0.9 https://trial.medpath.com/news/e72065edfab5b47e/eleva-advances-factor-h-therapy-cpv-104-into-first-in-human-trial-for-rare-kidney-disease-c3-glomerulopathy 2025-07-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/9d0bcedf9686bc3d/sun-pharma-implements-capa-at-halol-facility-while-addressing-usfda-compliance-issues-across-three-manufacturing-sites 2025-07-07T09:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ad487a9ecf7b91a/pulsesight-therapeutics-doses-first-patient-in-phase-i-trial-of-pst-611-for-dry-amd 2025-07-07T08:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/6e5178dc5f01f1c8/liquid-fat-supplement-shows-promise-in-treating-rare-childhood-disease-ataxia-telangiectasia 2025-07-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/41eb21e330db9de2/amicus-therapeutics-secures-japan-approval-for-pombiliti-opfolda-combination-therapy-for-late-onset-pompe-disease 2025-07-06T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/19ee0c5c611cf103/comprehensive-review-reveals-therapeutic-potential-of-m6a-regulatory-protein-inhibitors-in-cancer-treatment 2025-07-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aebf438c52058e2d/emcure-pharmaceuticals-acquires-full-control-of-zuventus-healthcare-in-724-9-crore-deal 2025-07-06T14:21:55+00:00 hourly 0.9 https://trial.medpath.com/news/5f97c0ee720abcbc/thailand-achieves-pharmaceutical-independence-with-first-domestically-produced-targeted-cancer-drugs 2025-07-06T13:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/cc75ccc14f7663e5/cdsco-expert-committee-accepts-pfizer-s-phase-iii-data-for-abrocitinib-in-atopic-dermatitis 2025-07-06T13:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/29245e2b53464b13/drdo-and-aiims-rishikesh-partner-for-clinical-trials-of-biomedical-devices-in-extreme-environments 2025-07-06T13:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/9dda49864e208f20/eli-lilly-and-loxo-oncology-advance-phase-3-trial-testing-pirtobrutinib-combination-for-previously-treated-cll-sll 2025-07-06T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/ea9272bf3b8dc0f5/andhra-pradesh-establishes-first-cdsco-notified-medical-device-auditing-body-to-streamline-regulatory-compliance 2025-07-06T00:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/c6bdba43aa80f9de/celltrion-prepares-european-launch-of-subcutaneous-infliximab-biosimilar-following-positive-regulatory-opinion 2025-07-05T20:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/836fae862fb4a87b/abu-dhabi-partners-with-children-s-national-hospital-to-advance-pediatric-cell-and-gene-therapy 2025-07-05T09:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/071b39410fb2eef2/spectral-medical-advances-pmx-hemoperfusion-device-toward-fda-approval-for-septic-shock-treatment 2025-07-05T09:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/e682b50d39495289/viemed-healthcare-completes-28m-acquisition-of-lehan-s-medical-equipment-to-expand-respiratory-care-services 2025-07-05T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c7f983946dbfe23/sanofi-advances-multiple-phase-2-trials-targeting-rare-kidney-diseases-and-ulcerative-colitis 2025-07-05T05:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/b57ebee3d97b00c7/btk-inhibitors-show-promise-for-progressive-ms-as-current-therapies-fall-short 2025-07-05T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/b3f44607076a078a/sanofi-launches-long-term-safety-study-for-tzield-in-stage-2-type-1-diabetes-patients 2025-07-05T00:40:32+00:00 hourly 0.9 https://trial.medpath.com/news/b7cf2109010681c9/arrivent-biopharma-raises-75-million-to-advance-firmonertinib-and-cancer-pipeline 2025-07-05T00:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/f9a9126f605375bd/gallant-raises-18m-to-develop-first-fda-approved-off-the-shelf-stem-cell-therapy-for-pets 2025-07-05T00:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/efcd19c8e54fec55/mcmaster-s-inhaled-covid-19-vaccine-shows-promise-in-phase-1-trials-advances-to-phase-2 2025-07-04T22:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/86552a1f783520a1/steep-hill-terminates-acquisition-of-obesity-focused-biotech-lir-life-sciences 2025-07-04T22:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/b500a9d972dd43b9/first-human-trial-of-regenerative-cell-therapy-for-sensorineural-hearing-loss-receives-uk-approval 2025-07-04T22:00:37+00:00 hourly 0.9 https://trial.medpath.com/news/cab1d35fd74ac0c3/first-us-nasal-covid-19-vaccine-shows-67-infection-reduction-in-phase-1-trial 2025-07-04T20:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/dbfb45de1c6fdedb/spectral-medical-files-100-million-shelf-prospectus-ahead-of-septic-shock-treatment-milestones 2025-07-04T20:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/ad7b893061bbb679/lupin-launches-generic-ipratropium-bromide-nasal-spray-in-us-market 2025-07-04T20:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/0887630fad3e4698/shilpa-pharma-lifesciences-unit-1-passes-brazilian-anvisa-gmp-inspection-with-no-critical-findings 2025-07-04T17:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/fa4583f8719b6f9c/particle-dynamics-acquires-euroapi-uk-spray-drying-facility-to-expand-global-cdmo-capabilities 2025-07-04T17:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/0f36346bf4ce7181/precisio-biotix-achieves-first-in-human-dosing-of-clyo-lysin-for-multi-drug-resistant-prosthetic-joint-infection 2025-07-04T14:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/490344895ee7da29/serendipity-space-secures-pre-seed-funding-to-advance-microgravity-based-pharmaceutical-manufacturing 2025-07-04T12:40:48+00:00 hourly 0.9 https://trial.medpath.com/news/8cfefb1db06f6478/gene-therapy-for-fabry-disease-shows-promise-with-3-7-million-cost-savings-in-early-stage-trial 2025-07-04T12:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/40be1769d0d40dd9/spineway-secures-gmed-approval-for-new-esp-prostheses-production-line-doubles-manufacturing-capacity 2025-07-04T10:54:42+00:00 hourly 0.9 https://trial.medpath.com/news/c73539bfa207a976/novel-nasal-antibody-treatment-shows-promise-for-hay-fever-prevention-in-preclinical-study 2025-07-04T09:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/041b6db8b044027b/everest-medicines-advances-ai-powered-mrna-platform-with-cancer-vaccine-breakthroughs 2025-07-04T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/6f6e520c500075c7/ab-science-s-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer 2025-07-04T09:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/32f71a1cd192e4f1/shimadzu-receives-fda-clearance-for-high-resolution-positview-pet-system-for-alzheimer-s-diagnosis 2025-07-04T08:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/682ddee20919759b/lunit-partners-with-microsoft-to-develop-ai-powered-cancer-diagnostic-tools-on-azure-platform 2025-07-04T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/785a5555d6cb25bc/bioatla-s-ba3182-shows-tumor-shrinkage-across-multiple-cancer-types-in-phase-1-trial 2025-07-04T06:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/5011b4e8754a2334/imugene-secures-au-5-87-million-r-d-tax-refund-to-advance-immuno-oncology-pipeline 2025-07-04T06:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/96ef739edb7cf350/brii-biosciences-licenses-novel-antibiotic-brii-693-to-joincare-group-for-greater-china-market 2025-07-04T06:29:16+00:00 hourly 0.9 https://trial.medpath.com/news/c21737a4a20b5470/vertex-s-casgevy-shows-sustained-efficacy-in-long-term-follow-up-data-for-sickle-cell-disease-and-beta-thalassemia 2025-07-04T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/0e823404daee4de3/editas-medicine-achieves-90-ldl-cholesterol-reduction-with-edit-401-gene-therapy-in-preclinical-studies 2025-07-04T06:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/5a6f38ced7c8b2f0/gilead-sciences-advances-sacituzumab-govitecan-studies-across-multiple-cancer-types 2025-07-04T06:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/34ae0e310d060eb0/inventiva-s-lanifibranor-shows-promise-in-reversing-liver-vascular-damage-in-mash-patients 2025-07-04T06:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/d25f1c3a532537da/godavari-biorefineries-secures-european-patent-for-novel-anticancer-molecule-targeting-cancer-stem-cells 2025-07-04T05:56:19+00:00 hourly 0.9 https://trial.medpath.com/news/dd2036fdc7201b45/fda-approves-thermo-fisher-s-rapid-ngs-companion-diagnostic-for-zegfrovy-in-nsclc 2025-07-04T05:54:50+00:00 hourly 0.9 https://trial.medpath.com/news/7603a9c7bd4fafb2/monte-rosa-s-ai-powered-discovery-engine-expands-molecular-glue-degrader-target-space-in-science-publication 2025-07-04T05:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/911702a0f0fc3f7f/fluorescent-drug-bevonescein-shows-promise-for-nerve-sparing-surgery-in-phase-1-2-trial 2025-07-04T05:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/557bb75cdb6353f7/ebenbuild-secures-eur2-3-million-eic-grant-to-advance-digital-twin-platform-for-respiratory-drug-development 2025-07-04T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/4170fc457891cefc/alembic-pharmaceuticals-acquires-utility-therapeutics-to-commercialize-first-new-uti-antibiotic-in-20-years 2025-07-04T05:46:13+00:00 hourly 0.9 https://trial.medpath.com/news/a0607d7d5ac97c43/quebec-expands-public-reimbursement-of-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-07-04T05:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/b88ce718d6fbb0e5/astrazeneca-and-summit-therapeutics-in-advanced-talks-for-15-billion-ivonescimab-licensing-deal 2025-07-04T05:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/00e0718e877c7fea/mira-s-non-psychoactive-cannabis-analog-mira-55-matches-morphine-s-pain-relief-without-opioid-risks-in-preclinical-study 2025-07-04T05:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/8f59ae860bdc7818/stallergenes-greer-transitions-actair-r-promotional-activities-from-shionogi-to-ceolia-in-japan 2025-07-04T05:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/09f79395463c9e07/eqt-healthcare-growth-acquires-europa-biosite-to-expand-life-sciences-distribution-network 2025-07-04T05:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/af7ef6ae0f36fe70/stereotaxis-magic-catheter-demonstrates-94-acute-efficacy-in-first-in-human-cardiac-ablation-study 2025-07-04T05:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/0e5a23e9515954bf/iqure-pharma-appoints-former-ucb-chief-medical-officer-iris-loew-friedrich-as-clinical-and-r-d-advisor 2025-07-04T05:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/12b9ce09b4f3b0dc/rdp-pharma-and-singapore-s-eddc-partner-to-develop-protein-degrader-therapies-for-autoimmune-diseases 2025-07-04T05:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/955c1cc8cc87f28a/oxford-biotherapeutics-and-boehringer-ingelheim-advance-third-oncology-drug-candidate-to-ind-enabling-studies 2025-07-04T04:55:49+00:00 hourly 0.9 https://trial.medpath.com/news/07efdbd03b6a2f62/island-pharmaceuticals-raises-6-22-million-to-advance-dengue-fever-treatment-and-antiviral-pipeline 2025-07-04T04:54:17+00:00 hourly 0.9 https://trial.medpath.com/news/a0d03b689fc6b5a4/neurizon-secures-global-license-with-elanco-for-als-drug-nuz-001-accelerating-path-to-market 2025-07-04T04:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/1b2cfcadaa035453/aquestive-therapeutics-receives-fda-approval-for-anaphylm-new-drug-application-targeting-2-billion-severe-allergic-reaction-market 2025-07-04T04:52:21+00:00 hourly 0.9 https://trial.medpath.com/news/25c9425a929b608d/integra-lifesciences-launches-pediatric-registry-for-aera-eustachian-tube-balloon-dilation-system 2025-07-04T04:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/54debe5fab3e60b7/auriga-research-partners-with-san-francisco-research-institute-to-advance-ai-driven-clinical-research-across-global-markets 2025-07-04T04:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/dcaf31eaacecf3a1/crispr-therapeutics-ctx310-shows-promising-lipid-reduction-results-in-phase-1-trial 2025-07-04T04:50:36+00:00 hourly 0.9 https://trial.medpath.com/news/806643c64cf7d629/novartis-cosentyx-fails-to-meet-primary-endpoint-in-phase-iii-giant-cell-arteritis-trial 2025-07-04T04:46:51+00:00 hourly 0.9 https://trial.medpath.com/news/2f47143b58850348/hls-therapeutics-secures-nova-scotia-reimbursement-for-vascepa-expanding-cardiovascular-drug-access-to-95-of-eligible-canadians 2025-07-04T04:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/16a1463f1ea7d746/theratechnologies-agrees-to-254-million-private-acquisition-by-cb-biotechnology 2025-07-04T04:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/deb462db883cb752/jacobio-pharma-receives-ind-acceptance-for-bet-inhibitor-jab-8263-in-autoimmune-diseases 2025-07-04T04:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/433db9dcd5a376e9/astrazeneca-completes-phase-3b-asthma-study-evaluating-hfo-mdi-safety-and-launches-china-observational-study 2025-07-04T04:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/f89e4e04f8e1c425/norwegian-researchers-report-promising-results-from-daratumumab-pilot-study-in-me-cfs-patients 2025-07-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2955c2494e20d635/nektar-therapeutics-raises-115-million-through-secondary-offering-to-fund-pipeline-development 2025-07-03T22:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/c1466edf131ba2c4/glucomodicum-s-needle-free-cgm-achieves-11-5-mard-in-646-patient-clinical-trial-nears-eu-regulatory-filing 2025-07-03T04:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/377c8ef6717f19f2/federal-judge-blocks-mass-layoffs-at-hhs-citing-likely-unlawful-staff-cuts 2025-07-03T04:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/a55ad6f9b8dfe926/fda-approves-first-triple-combination-hypertension-pill-as-june-2025-delivers-major-cardiovascular-advances 2025-07-03T04:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/15370d6fe4c9313b/fda-issues-safety-alert-for-abiomed-blood-pump-controllers-following-three-patient-deaths 2025-07-03T01:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/12e203c21ff60441/novel-tiancimycin-based-antibody-drug-conjugate-shows-promise-against-aggressive-lymphoma 2025-07-03T01:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/5a4e2aa4cae548cf/ucla-researchers-receive-3-5-million-nih-grant-to-develop-novel-mpox-antivirals-targeting-immune-evasion 2025-07-03T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/0ccbce51e0c5fbb7/fda-clears-first-ai-powered-wristband-for-essential-tremor-treatment 2025-07-03T00:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/02447b51948e720a/india-launches-first-indigenous-dengue-vaccine-phase-3-trial-with-over-10000-participants 2025-07-03T00:44:26+00:00 hourly 0.9 https://trial.medpath.com/news/85fe584eff49d887/otsuka-pharmaceutical-acquires-cantargia-s-can10-antibody-program-for-33-million-upfront-in-autoimmune-disease-deal 2025-07-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/103b02656c4f6d81/philips-receives-fda-clearance-for-ai-powered-mri-software-that-accelerates-scans-by-3x 2025-07-02T21:00:33+00:00 hourly 0.9 https://trial.medpath.com/news/d7227a746e30c600/bxcl701-plus-pembrolizumab-shows-early-promise-in-second-line-pancreatic-cancer-treatment 2025-07-02T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/cbbc5e763977c3dd/gsk-s-gepotidacin-receives-fda-priority-review-for-gonorrhea-treatment 2025-07-02T20:49:05+00:00 hourly 0.9 https://trial.medpath.com/news/3f154500c9afb9bb/novel-royalty-based-investment-fund-proposes-new-model-for-als-drug-development 2025-07-02T20:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/cea0e42441d37556/regener-eyes-receives-fda-closure-of-voluntary-recall-returns-to-full-operations-with-enhanced-safety-features 2025-07-02T20:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/476998358512f6b9/invivyd-forms-spear-study-group-to-investigate-monoclonal-antibody-therapy-for-long-covid 2025-07-02T20:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/2af849987cca7aa4/headlands-research-expands-to-caribbean-with-cmrcenter-acquisition-enhancing-hispanic-patient-access-to-clinical-trials 2025-07-02T20:25:37+00:00 hourly 0.9 https://trial.medpath.com/news/de5aa932d5c55bff/argon-ai-secures-5-5m-to-transform-pharmaceutical-data-management-with-ai-native-workspace 2025-07-02T20:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/fc86db8b27bbf375/delhi-high-court-orders-cdsco-to-review-safety-of-glp-1-diabetes-drugs-used-for-weight-loss 2025-07-02T17:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/da7fbcfe783b977b/bioversys-and-shionogi-form-strategic-partnership-to-develop-novel-ntm-treatments-worth-up-to-chf-484-million 2025-07-02T17:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/7a85454f7175d580/epo-and-upc-reach-opposite-conclusions-on-amgen-s-pcsk9-antibody-patent-validity 2025-07-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/511e4a3aed2450cf/ppp2r1a-mutations-predict-improved-survival-after-cancer-immunotherapy-in-ovarian-clear-cell-carcinoma 2025-07-02T17:22:52+00:00 hourly 0.9 https://trial.medpath.com/news/143a7b41db01581c/fidelio-capital-acquires-majority-stake-in-alphalyse-to-expand-lc-ms-host-cell-protein-testing-globally 2025-07-02T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/0fd950d74b2c3fc3/organon-discontinues-endometriosis-drug-og-6219-after-phase-ii-trial-failure 2025-07-02T17:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/5e3cee3c72a9f743/bio-thera-s-bat4406f-achieves-early-trial-success-in-rare-neurological-disorder-nmosd 2025-07-02T17:14:22+00:00 hourly 0.9 https://trial.medpath.com/news/fd9a3b033a2ed17f/primo-biotechnology-raises-nt-220m-series-a-to-advance-radioligand-theranostics-platform 2025-07-02T17:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/30f0dbe5a291819a/hemostemix-launches-commercial-sales-of-vescell-stem-cell-therapy-in-florida-under-new-legislation 2025-07-02T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/7c8906b0959f8d77/hikma-receives-fda-approval-for-tyzavantm-first-ready-to-infuse-vancomycin-formulation-for-sepsis-treatment 2025-07-02T17:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/37db87e7191fe599/kim-1-emerges-as-promising-prognostic-biomarker-in-advanced-renal-cell-carcinoma 2025-07-02T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/7df0dd791bfb64b3/jcr-pharmaceuticals-completes-enrollment-in-global-phase-iii-trial-for-blood-brain-barrier-penetrating-hunter-syndrome-therapy 2025-07-02T17:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/a0fb9957c86a41ac/belite-bio-completes-enrollment-in-phase-3-phoenix-trial-for-geographic-atrophy-treatment 2025-07-02T16:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/1e00d5d9be2b2901/capsule-sponge-test-shows-promise-as-alternative-to-endoscopy-for-barrett-s-esophagus-monitoring 2025-07-02T16:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/8bf1cb0fcff50328/federal-circuit-reverses-patent-board-ruling-on-eye-redness-treatment-strengthens-brimonidine-patent-protection 2025-07-02T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/9949aa55e5cd98ee/rbc-capital-raises-xenon-pharmaceuticals-price-target-to-57-based-on-phase-iii-epilepsy-drug-optimism 2025-07-02T13:52:25+00:00 hourly 0.9 https://trial.medpath.com/news/b82934a685036403/adaptive-biotechnologies-integrates-clonoseq-mrd-testing-into-flatiron-health-s-oncoemr-platform 2025-07-02T13:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/ba52eb2beffb633f/australia-opens-first-antibody-drug-conjugate-manufacturing-facility-to-advance-precision-cancer-treatment 2025-07-02T08:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/f9979c6259854cdc/china-launches-commercial-insurance-catalog-to-accelerate-innovative-drug-development 2025-07-02T04:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/2b74a590361e5b3d/biocon-races-to-launch-first-generic-semaglutide-in-canada-as-wegovy-patents-expire 2025-07-02T04:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/a5e90fcfcad872bb/neurocrine-biosciences-advances-cah-treatment-portfolio-with-long-acting-injectable-therapy 2025-07-02T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/c11f04a02165a7b1/nyu-engineers-develop-first-immunocompetent-leukemia-on-a-chip-device-to-advance-car-t-cell-therapy-testing 2025-07-02T03:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/c25b55c5cb29da80/catalio-capital-closes-400m-fund-iv-to-back-healthcare-and-biotech-companies-amid-market-downturn 2025-07-02T02:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/5d44246f663b8b84/astrazeneca-ceo-reportedly-considers-us-stock-listing-move-amid-uk-regulatory-frustrations 2025-07-02T02:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/3a4f8838babb6ed7/outlook-therapeutics-approaches-critical-fda-decision-for-lytenava-as-european-launch-validates-market-potential 2025-07-02T01:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/0e9914db14233e57/simtra-biopharma-solutions-completes-major-facility-expansion-in-germany-to-meet-growing-injectable-therapeutics-demand 2025-07-02T01:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/bf332a5d11415bc9/first-oral-drug-ma-5-shows-promise-for-rare-barth-syndrome-in-preclinical-studies 2025-07-02T01:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/8118cccb7fe183fb/lixte-biotechnology-secures-5-million-private-placement-to-advance-cancer-therapy-development 2025-07-02T00:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/120876a489fae230/lixte-biotechnology-secures-5m-funding-for-cancer-therapy-development-stock-surges-55 2025-07-02T00:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/58702cba62895133/house-republicans-subpoena-former-pfizer-executive-over-alleged-covid-19-vaccine-trial-delays 2025-07-02T00:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/68d8d3c4a8050f25/onward-medical-submits-fda-510-k-application-for-home-use-of-arc-ex-spinal-cord-stimulation-system 2025-07-02T00:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/6f3726f963643922/oruka-therapeutics-promotes-laura-sandler-to-coo-as-company-advances-novel-psoriasis-pipeline 2025-07-01T23:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/425639a0a9900968/quiver-bioscience-secures-2-15m-nih-grant-to-develop-ai-powered-cns-drug-safety-platform 2025-07-01T23:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/50f717a9af525b7d/meiragtx-advances-gene-therapy-pipeline-with-fda-rmat-designation-and-pivotal-trial-progress 2025-07-01T23:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/cf836f133c9e22cd/inhalation-sciences-secures-recurring-orders-from-global-pharma-customer-strengthening-preclinical-research-platform 2025-07-01T22:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/1db2184118023659/breakthrough-mrna-vaccine-shows-promise-against-deadly-elephant-virus-in-first-real-world-test 2025-07-01T21:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/4df9f2bde733e2b4/carthera-s-sonocloud-system-receives-ema-orphan-medical-device-endorsement-for-brain-tumor-treatment 2025-07-01T20:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/3f00e577a6058ab7/sartorius-completes-80-million-acquisition-of-mattek-to-advance-3d-cell-model-technology 2025-07-01T20:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/32e4a5286840ba52/hanchorbio-secures-202m-licensing-deal-with-henlius-for-novel-cd47-targeting-cancer-immunotherapy 2025-07-01T20:30:08+00:00 hourly 0.9 https://trial.medpath.com/news/b235c418bc985770/rush-university-medical-center-launches-first-ever-apple-vision-pro-colonoscopy-study-with-ai-integration 2025-07-01T20:29:07+00:00 hourly 0.9 https://trial.medpath.com/news/06f0c57e8d4279f9/redhill-biopharma-launches-precision-medicine-phase-2-trial-combining-opaganib-with-darolutamide-for-advanced-prostate-cancer 2025-07-01T20:29:05+00:00 hourly 0.9 https://trial.medpath.com/news/dd5033591ccf5a8d/feliqs-secures-9-million-series-a-to-advance-novel-rop-prevention-therapy-flq-101 2025-07-01T20:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/c2d1f9658f84261a/celltrion-advances-pembrolizumab-biosimilar-development-as-herceptin-copy-nears-european-launch 2025-07-01T19:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/a7c4d8e3274c2a82/bluebird-bio-strengthens-leadership-team-with-three-key-executive-appointments 2025-07-01T19:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/5c0c159adbf6e080/sonoclear-system-receives-fda-breakthrough-device-designation-for-enhanced-brain-tumor-surgery-imaging 2025-07-01T19:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/ee6445be95773edb/senzime-secures-major-u-s-hospital-contract-and-new-patent-for-tetragraph-neuromuscular-monitoring-system 2025-07-01T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/47f2725461af0445/wuxi-xdc-completes-singapore-manufacturing-facility-expanding-global-bioconjugate-production-network 2025-07-01T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/e0359d2cf960d307/biovaxys-advances-dpx-platform-as-alternative-to-lipid-nanoparticles-for-mrna-vaccine-delivery 2025-07-01T17:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/d8ba7b814ba96314/arctic-bioscience-s-hro350-shows-promise-in-phase-2b-psoriasis-trial-despite-missing-primary-endpoint 2025-07-01T17:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/35eb4035cd69a37d/inmagene-initiates-phase-2b-trial-of-img-007-anti-ox40-antibody-for-moderate-to-severe-atopic-dermatitis 2025-07-01T17:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/4f535949398a6993/adiposs-secures-chf-4-million-series-a-to-advance-brown-fat-imaging-technology-for-cancer-treatment-prediction 2025-07-01T17:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/608a63f9e9f3f97f/pixelgen-technologies-secures-14-7m-eic-funding-to-advance-single-cell-protein-interactome-analysis-platform 2025-07-01T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/033d49cc5f09d1a0/ns-pharma-and-boston-children-s-hospital-form-strategic-alliance-to-advance-rare-disease-therapies 2025-07-01T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/c0010e773ad36875/pfizer-terminates-phase-ii-cd47-trial-in-blood-cancer-due-to-recruitment-challenges 2025-07-01T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/c9d2502efb2b5664/soligenix-completes-manufacturing-transfer-of-synthetic-hypericin-for-rare-skin-cancer-treatment 2025-07-01T17:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/808cd16db1949a91/pharmnovo-advances-non-addictive-neuropathic-pain-drug-pn6047-with-phase-2-trial-application 2025-07-01T17:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/2fee716ab869d4f1/sandoz-invests-1-1-billion-in-european-biosimilar-manufacturing-hub-to-capture-222-billion-market-opportunity 2025-07-01T17:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/84f273c416e36e5c/argenx-partners-with-unnatural-products-in-1-5-billion-macrocyclic-peptide-deal 2025-07-01T16:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/63d9bf873cb5429b/bio-usawa-and-bioeq-ag-partner-to-bring-ranibizumab-biosimilar-to-sub-saharan-africa 2025-07-01T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/56e34e7f540d3b63/arthrosi-therapeutics-achieves-rapid-enrollment-milestone-in-phase-3-gout-trial-for-pozdeutinurad 2025-07-01T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/c3a8788570dffc4f/imagene-ai-secures-23m-series-b-led-by-larry-ellison-to-advance-multi-modal-foundation-models-for-precision-medicine 2025-07-01T16:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/6ab1216ffab4d2b1/oragenics-raises-20-million-to-advance-concussion-treatment-clinical-trials 2025-07-01T16:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/69afcab1ade520fe/intrabio-completes-phase-iii-recruitment-for-ataxia-telangiectasia-treatment-in-record-time 2025-07-01T16:20:34+00:00 hourly 0.9 https://trial.medpath.com/news/0204885d396f87af/imunon-secures-nasdaq-listing-extension-to-advance-phase-3-ovarian-cancer-immunotherapy 2025-07-01T16:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/6a81c5325c1cc916/oncternal-therapeutics-sells-ror1-targeting-programs-to-ho-ola-therapeutics-for-68-million-deal 2025-07-01T12:56:40+00:00 hourly 0.9 https://trial.medpath.com/news/4dcfeae36e15be6b/verrica-pharmaceuticals-launches-global-phase-3-trial-for-ycanth-in-common-warts-targeting-22-million-us-patients 2025-07-01T12:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/dd49a892447a2c0e/ribociclib-kisqali-added-to-pbs-for-early-stage-breast-cancer-patients-in-australia 2025-07-01T12:55:35+00:00 hourly 0.9 https://trial.medpath.com/news/61728c3b404405d9/lutroo-imaging-initiates-first-in-human-trial-of-radiocainetm-pet-tracer-for-pain-visualization 2025-07-01T12:54:43+00:00 hourly 0.9 https://trial.medpath.com/news/53558de56b6ab951/beacon-therapeutics-licenses-abeona-s-aav204-gene-therapy-platform-for-retinal-disease-treatment 2025-07-01T12:54:36+00:00 hourly 0.9 https://trial.medpath.com/news/bfe34a5a72114e18/atai-life-sciences-secures-50-million-private-placement-to-advance-psychedelic-mental-health-therapies 2025-07-01T12:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/93a009f6f364805f/apellis-secures-300-million-in-non-dilutive-financing-through-sobi-royalty-agreement-for-rare-kidney-disease-therapy 2025-07-01T12:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/2894baf96605edf6/hengrui-pharmaceutical-secures-nmpa-approval-for-jak1-inhibitor-ivarmacitinib-in-severe-alopecia-areata 2025-07-01T12:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/59e9266913cba382/empnia-receives-fda-clearance-for-emotus-respiratory-motion-management-system-in-radiation-therapy 2025-07-01T12:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/d578612f90237d7c/genenta-reports-3-year-survival-in-glioblastoma-patients-with-temferon-cell-therapy 2025-07-01T12:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/f6ebb3ebebeba5df/sigvotatug-vedotin-shows-promise-in-nsclc-as-novel-integrin-beta-6-targeted-adc-advances-to-phase-3 2025-07-01T12:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/9c10494c297ac268/avacta-strengthens-leadership-team-with-appointment-of-chief-medical-officer-and-business-development-advisor 2025-07-01T09:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/7bfdbc54672164be/healx-partners-with-sci-ventures-in-2m-ai-driven-initiative-to-develop-spinal-cord-injury-treatments 2025-07-01T09:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/c11e30febf8531d4/drc-medicine-announces-422-million-spac-merger-to-advance-therapeutic-mask-technology-and-parkinson-s-drug-pipeline 2025-07-01T08:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/4116baaa00cf7e86/capsule-sponge-test-combined-with-biomarkers-shows-promise-for-barrett-esophagus-risk-stratification 2025-07-01T04:53:29+00:00 hourly 0.9 https://trial.medpath.com/news/8b0dd0a93b1699cc/tempus-ai-raises-650-million-through-convertible-notes-to-advance-ai-driven-precision-medicine-platform 2025-07-01T04:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/4cc9013d08443d26/fda-clears-ind-for-iks014-her2-targeted-adc-enabling-us-clinical-trial-expansion 2025-07-01T04:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/6b1bd7547e1ecebc/third-line-mcrc-treatment-landscape-evolves-with-multiple-sequential-options-offering-modest-survival-benefits 2025-07-01T02:54:08+00:00 hourly 0.9 https://trial.medpath.com/news/4702afb17dd5c620/ambroxol-shows-promise-in-slowing-parkinson-s-disease-dementia-in-phase-ii-clinical-trial 2025-07-01T02:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/daf2bbb40027c197/neurocrine-biosciences-initiates-phase-1-trial-for-long-acting-cah-treatment-nbip-01435 2025-07-01T00:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/04cb766105369e9a/somai-pharmaceuticals-acquires-rpk-biopharma-strengthening-global-cannabis-manufacturing-leadership 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/38a6016e89e03bc7/ich-releases-draft-e20-guideline-on-adaptive-clinical-trial-designs-for-global-harmonization 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/8059f2dabc314b67/radiotherapy-immunotherapy-combinations-show-promise-for-enhanced-cancer-treatment-through-abscopal-effects 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6caa1795ebc7ba6b/chemoimmunotherapy-shows-limited-efficacy-in-younger-patients-with-extensive-stage-small-cell-lung-cancer 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7895057a6650290c/major-pharma-companies-face-massive-revenue-losses-as-patent-cliff-hits-key-blockbusters 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e07f54d89250d6a6/astrazeneca-launches-phase-1b-2-trial-of-dual-car-t-therapy-azd0120-for-refractory-systemic-lupus-erythematosus 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c4fd282895349cd/real-world-safety-analysis-reveals-new-cardiovascular-risks-for-hyperkalemia-drug-sodium-zirconium-cyclosilicate 2025-07-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e410c4d28f7231d6/protagonist-therapeutics-advances-pn-477-triple-agonist-for-obesity-treatment-targeting-same-mechanism-as-eli-lilly-s-retatrutide 2025-06-30T23:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/51503ba62022a832/artelo-biosciences-stock-surges-over-130-following-positive-preclinical-depression-data-and-first-in-human-pain-trial-results 2025-06-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/4cfc9353faf721a6/fda-mandates-new-safety-warnings-for-adhd-stimulants-in-children-under-six 2025-06-30T21:11:59+00:00 hourly 0.9 https://trial.medpath.com/news/48ca2a99d4664fb0/partial-breast-radiation-proves-non-inferior-to-whole-breast-treatment-in-10-year-follow-up-of-uk-import-low-trial 2025-06-30T20:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/1934ded43c1f3dea/uc-davis-health-enrolls-first-patient-in-novel-carotid-stent-trial-targeting-stroke-prevention 2025-06-30T20:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/5e0f120d51620176/novel-bispecific-antibody-shows-promise-for-autoimmune-disease-treatment-in-preclinical-studies 2025-06-30T19:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/a3f01234a61ad3ec/crispr-screen-reveals-key-to-enhancing-rna-drug-efficacy-through-endosomal-transport-modulation 2025-06-30T19:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/a5fb4593c78fd2c7/zilucoplan-shows-sustained-efficacy-and-steroid-sparing-benefits-in-long-term-myasthenia-gravis-treatment 2025-06-30T18:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/8eb82ada07050c1b/applied-dna-sciences-restructures-operations-to-focus-on-synthetic-dna-manufacturing-for-gene-therapies 2025-06-30T18:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/4e9eb384f842a900/biofrontera-acquires-full-us-rights-to-ameluz-and-rhodoled-secures-11m-funding 2025-06-30T16:45:50+00:00 hourly 0.9 https://trial.medpath.com/news/c0c76a4a9531a775/cd19-car-t-cell-therapy-shows-promise-in-relapsed-t-8-21-aml-despite-short-term-remission 2025-06-30T16:43:27+00:00 hourly 0.9 https://trial.medpath.com/news/b0913a258790104f/avencell-secures-40-million-amed-grant-to-advance-dual-antigen-allogeneic-car-t-therapy-for-b-cell-lymphomas 2025-06-30T16:43:19+00:00 hourly 0.9 https://trial.medpath.com/news/66d7c5759ec09102/abbvie-acquires-capstan-therapeutics-for-2-1-billion-to-advance-in-vivo-car-t-technology-for-autoimmune-diseases 2025-06-30T16:43:14+00:00 hourly 0.9 https://trial.medpath.com/news/77f78d9a52819d69/atezolizumab-plus-bevacizumab-emerges-as-optimal-first-line-treatment-for-advanced-hepatocellular-carcinoma 2025-06-30T16:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/9d54e740d60d7192/assembly-biosciences-initiates-phase-1b-trial-of-long-acting-hsv-helicase-primase-inhibitor-abi-1179 2025-06-30T16:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/53501f085533bb26/logicflo-ai-secures-2-7m-to-deploy-ai-agents-across-life-sciences-operations 2025-06-30T16:36:07+00:00 hourly 0.9 https://trial.medpath.com/news/092eec0126d94fd4/abbvie-acquires-in-vivo-car-t-developer-capstan-therapeutics-for-up-to-2-1-billion 2025-06-30T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/efbfdcf5e4e7c2b9/meta-analysis-reveals-mixed-benefits-of-first-line-vs-second-line-cdk4-6-inhibitor-therapy-in-hr-her2-metastatic-breast-cancer 2025-06-30T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/bc023e3257dc6b64/akeso-s-bispecific-antibody-success-from-3m-startup-to-15b-global-biotech-leader 2025-06-30T16:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/fd914e369840ddcd/alpha-fusion-and-curadh-form-strategic-partnership-to-advance-astatine-211-radiopharmaceuticals 2025-06-30T16:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/3ef103fd3ced42f2/revolution-medicines-and-summit-therapeutics-launch-clinical-collaboration-to-test-ras-inhibitor-combinations-with-bispecific-antibody 2025-06-30T16:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/5fbbc5e87a5e605d/fda-grants-breakthrough-device-designation-to-toby-s-ai-powered-urine-test-for-bladder-cancer-detection 2025-06-30T16:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/1781efbae982b9ba/spectral-ai-submits-de-novo-fda-application-for-ai-powered-burn-assessment-device 2025-06-30T16:30:48+00:00 hourly 0.9 https://trial.medpath.com/news/9ca228aba42d2729/canada-s-pmprb-releases-new-drug-price-review-guidelines-implementing-two-step-process-starting-january-2026 2025-06-30T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/2fa5f9e335ca55df/portal-biotech-secures-35m-series-a-to-commercialize-world-s-first-full-length-single-molecule-protein-sequencer 2025-06-30T16:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/a304e2e03e8391df/fda-approves-takeda-s-gammagard-liquid-erc-first-ready-to-use-low-iga-immunoglobulin-therapy-for-primary-immunodeficiency 2025-06-30T16:18:56+00:00 hourly 0.9 https://trial.medpath.com/news/e25c9caab616385f/fda-accepts-review-of-skinvive-by-juvederm-for-neck-line-treatment-expansion 2025-06-30T16:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/da957cb0520b700d/amgen-s-bemarituzumab-shows-significant-survival-benefit-in-phase-3-gastric-cancer-trial 2025-06-30T16:18:45+00:00 hourly 0.9 https://trial.medpath.com/news/7938c35fe61fd6ee/dual-ctla-4-and-pd-1-blockade-shows-superior-efficacy-in-melanoma-brain-metastases 2025-06-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b0bcdd1ccabaae0c/pembrolizumab-vorinostat-combination-shows-promise-in-recurrent-squamous-cell-carcinoma 2025-06-30T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/news/636c4cea2af93cee/laverock-therapeutics-raises-ps20m-in-expanded-seed-funding-reports-positive-data-for-cancer-cell-therapy-programs 2025-06-30T12:58:38+00:00 hourly 0.9 https://trial.medpath.com/news/9f82bf216f01a1be/vetter-breaks-ground-on-285-million-clinical-manufacturing-facility-in-illinois 2025-06-30T12:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/ecba5581d15b7279/epigenica-secures-2-2m-to-advance-high-throughput-epigenetic-screening-platform 2025-06-30T12:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/9f78abd006d0c012/china-approves-orpathys-tagrisso-combination-for-egfr-mutated-lung-cancer-with-met-amplification 2025-06-30T12:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/f7df6882f6a67f59/iterum-therapeutics-appoints-christine-coyne-as-chief-commercial-officer-to-lead-orlynvah-launch 2025-06-30T12:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/8c972d3b179653ac/bridgebio-secures-300-million-royalty-financing-to-support-attr-cm-drug-launch 2025-06-30T12:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/6a03cb3161c94147/wuxi-biologics-launches-wuxihigh22-0-platform-achieving-record-230-mg-ml-protein-concentrations 2025-06-30T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/7c2b244a69ac4b7b/celcuity-s-gedatolisib-shows-promising-results-in-prostate-and-breast-cancer-trials 2025-06-30T12:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/cf90687bf4da7ad0/an2-therapeutics-completes-200-patient-study-revealing-40-mortality-rate-in-acute-melioidosis 2025-06-30T12:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/25869a730bdf147b/marksans-pharma-subsidiary-receives-fda-establishment-inspection-report-following-new-york-facility-review 2025-06-30T08:58:01+00:00 hourly 0.9 https://trial.medpath.com/news/562b2a4ada04cf77/neurizon-therapeutics-develops-oral-liquid-formulation-of-nuz-001-for-als-patients-with-swallowing-difficulties 2025-06-30T08:57:53+00:00 hourly 0.9 https://trial.medpath.com/news/2064948e43765f4d/faron-research-reveals-novel-immune-evasion-mechanism-validates-bexmarilimab-s-therapeutic-approach 2025-06-30T08:57:51+00:00 hourly 0.9 https://trial.medpath.com/news/1f6cce61f0f9cf04/esteve-acquires-caprelsa-rights-from-sanofi-to-expand-rare-cancer-treatment-portfolio 2025-06-30T08:54:15+00:00 hourly 0.9 https://trial.medpath.com/news/2f2911ef19af766e/roche-announces-leadership-changes-as-head-of-pharma-r-d-hans-clevers-retires 2025-06-30T08:53:30+00:00 hourly 0.9 https://trial.medpath.com/news/e94b5d56a43cd27e/argenx-advances-argx-119-to-registrational-study-for-ultra-rare-congenital-myasthenic-syndromes 2025-06-30T08:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/759eb979e18b83de/stalicla-secures-chf-2-million-financing-from-addex-therapeutics-to-advance-precision-medicine-for-autism-and-neurodevelopmental-disorders 2025-06-30T08:51:04+00:00 hourly 0.9 https://trial.medpath.com/news/87334aa0a98323f8/klotho-neurosciences-advances-gene-therapy-manufacturing-for-als-treatment 2025-06-30T08:50:45+00:00 hourly 0.9 https://trial.medpath.com/news/f8e00afec2524338/investor-challenges-avadel-board-over-alleged-lumryz-launch-mismanagement 2025-06-30T04:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/6542df0fd5d3bf20/ltr-pharma-s-intranasal-erectile-dysfunction-treatment-spontan-demonstrates-470-faster-absorption-in-pivotal-study 2025-06-30T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb3777b8a9d9c54c/atai-life-sciences-reports-mixed-phase-2b-results-as-bpl-003-succeeds-while-inidascamine-falls-short 2025-06-30T04:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/e14147a4737423e8/fda-clears-rmit-developed-ingestible-gas-capsule-for-diagnosing-gut-motility-disorders 2025-06-30T04:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/23da39dd5ab90c17/aurinia-s-aritinercept-shows-promising-safety-and-efficacy-in-phase-1-trial-for-autoimmune-diseases 2025-06-30T04:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/75511031226a1386/spatial-molecular-imaging-reveals-critical-immune-response-patterns-in-pig-to-human-kidney-xenotransplantation 2025-06-30T00:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/56a3ce5fb1eb2fda/remdesivir-shows-modest-reduction-in-long-covid-risk-among-hospitalized-patients 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/44e203db9bfeee64/adhd-medication-benefits-diminish-as-prescription-rates-rise-swedish-study-reveals 2025-06-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4802362bf046972e/seven-year-us-safety-data-confirms-brodalumab-s-stable-risk-profile-in-psoriasis-treatment 2025-06-29T20:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/90d048b29b6a60a1/brain-imaging-reveals-why-parkinson-s-drug-levodopa-fails-some-patients 2025-06-29T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/e3d03b28c1198e8d/breakthrough-immunotherapy-advances-target-uveal-melanoma-s-resistance-mechanisms 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b28da721a92554b0/metabolomics-study-identifies-angiotensin-iv-as-highly-accurate-biomarker-for-tuberculosis-diagnosis 2025-06-29T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4502e5c107ccec7f/fda-approves-voranigo-vorasidenib-as-first-targeted-therapy-for-idh-mutant-glioma 2025-06-29T12:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/d901173b53c142bc/karnataka-government-seeks-dcgi-investigation-into-hcg-clinical-trial-ethics-violations 2025-06-29T05:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/94b50e23c7f23134/trichoscopy-emerges-as-key-diagnostic-tool-for-early-detection-and-differentiation-of-alopecia-types 2025-06-29T02:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/f085034359b4a285/car-t-therapy-linked-to-8-9-fold-increased-risk-of-secondary-t-cell-lymphoma-in-global-study 2025-06-29T01:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/2fe439915ffc6e64/icon-group-invests-18-7-million-in-advanced-radiotherapy-technology-partnership-with-varian-to-address-uk-cancer-care-gap 2025-06-29T01:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/5c6f48467d8f7007/cansino-biologics-launches-phase-3-covid-19-vaccine-trial-in-pakistan-despite-declining-case-numbers 2025-06-29T01:09:55+00:00 hourly 0.9 https://trial.medpath.com/news/27fe02f98b4a26b6/scientists-achieve-3d-printing-breakthrough-for-type-1-diabetes-treatment-using-functional-human-islets 2025-06-29T00:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/9516dc970fd5d2cb/china-medical-system-files-for-secondary-sgx-listing-to-expand-southeast-asia-operations 2025-06-28T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/6905ab050f2aabc8/quantum-biopharma-secures-600-private-placement-to-advance-multiple-sclerosis-drug-development 2025-06-28T20:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/76ce5a956240f421/inmune-bio-raises-19m-to-advance-alzheimer-s-neuroinflammation-therapy-ahead-of-pivotal-trial-results 2025-06-28T17:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/85eaf849510fcdce/lantheus-partners-with-pfizer-and-lumina-in-fibre-consortium-to-transform-fibrotic-disease-clinical-trials 2025-06-28T17:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/3f8f542766777f87/federal-court-rejects-johnson-johnson-s-340b-drug-pricing-rebate-model 2025-06-28T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/c22ecb0b2aef24c9/alzheimer-s-drug-market-sees-780-investment-surge-following-leqembi-and-kisunla-approvals 2025-06-28T17:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/4e4f73b8357df010/hikma-pharmaceuticals-commits-1-billion-to-expand-us-generic-medicine-manufacturing-through-2030 2025-06-28T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/98487b216b57d927/india-mandates-digital-only-applications-for-who-gmp-and-copp-certificates-through-ondls-portal 2025-06-28T13:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/4491b7cb1dcc900e/iridex-enrolls-first-patient-in-dame-trial-testing-micropulse-laser-as-adjunct-to-anti-vegf-therapy-for-severe-diabetic-macular-edema 2025-06-28T13:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/c40bc076569b4f4e/aurobindo-pharma-recalls-over-4600-bottles-of-acetaminophen-in-us-due-to-tablet-discoloration 2025-06-28T13:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/61c3aea2e02a2c48/cook-medical-issues-class-i-recall-of-beacon-tip-catheters-following-tip-separation-injuries 2025-06-28T11:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/27b9f222176790f9/torrent-pharma-advances-2-4-billion-acquisition-of-jb-chemicals-in-major-industry-consolidation-move 2025-06-28T08:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/0f3455496a9cb995/natural-polymers-emerge-as-promising-platform-for-advanced-insulin-delivery-systems 2025-06-28T08:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/59c7499ea5ae5975/xoma-royalty-corporation-to-acquire-turnstone-biologics-for-0-34-per-share-plus-contingent-value-rights 2025-06-28T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/e4b9d3e957fd7ba5/urine-dna-test-predicts-bladder-cancer-recurrence-after-immunotherapy-treatment 2025-06-28T05:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/68c4393174b17004/selinexor-maintenance-therapy-shows-sustained-benefit-in-tp53-wild-type-advanced-endometrial-cancer 2025-06-28T05:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/49feb982ccda6ec8/fda-grants-breakthrough-therapy-designation-for-daraxonrasib-in-kras-mutated-pancreatic-cancer 2025-06-28T04:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/efa8b579365b3fc3/paralyzed-veteran-becomes-first-neuralink-brain-computer-interface-recipient-at-university-of-miami 2025-06-28T04:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/fff295ba489e1bf6/nccn-guidelines-update-treatment-sequencing-for-metastatic-gastrointestinal-stromal-tumors 2025-06-28T03:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/dfb7c7bc1ed2a670/cellular-senescence-gene-signature-reveals-new-biomarkers-for-idiopathic-pulmonary-fibrosis 2025-06-28T03:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/6e6be1ff1d52a805/bcma-targeted-car-t-therapy-achieves-96-3-response-rate-in-relapsed-multiple-myeloma-study 2025-06-28T01:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/dbb319c5080b3882/fda-approves-gamifant-as-first-treatment-for-macrophage-activation-syndrome-in-still-s-disease 2025-06-28T00:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/d193ae312b8336f1/cessatech-reports-75-pain-reduction-in-pediatric-acute-pain-study-eyes-us-launch-by-end-2025 2025-06-28T00:10:35+00:00 hourly 0.9 https://trial.medpath.com/news/b2f6776a00b290e4/retinalgenix-partners-with-labcorp-to-launch-dna-gps-platform-for-genetic-and-retinal-disease-screening 2025-06-27T21:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/6dd6042afacb7450/prd-therapeutics-initiates-first-in-human-trial-of-soat2-selective-inhibitor-prd001-for-rare-cholesterol-disorders 2025-06-27T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/3487c3c4fa380944/bioporto-launches-pronephro-aki-diagnostic-test-in-us-market-through-roche-partnership 2025-06-27T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/8a8bd82ecc25cfe5/fda-approved-tovorafenib-offers-new-treatment-option-for-pediatric-low-grade-glioma-with-braf-v600-mutations 2025-06-27T20:46:59+00:00 hourly 0.9 https://trial.medpath.com/news/7ee2d5edb3901bc9/patient-derived-esophageal-cancer-organ-chips-accurately-predict-chemotherapy-response-in-clinical-study 2025-06-27T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/9f3a2d2c43a7107f/gene-therapy-normalizes-brain-blood-flow-in-sickle-cell-disease-patients-reducing-stroke-risk 2025-06-27T20:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/4ea3d8688a5a3211/novel-vms-therapy-shows-early-promise-in-improving-quality-of-life-for-breast-cancer-patients 2025-06-27T16:54:07+00:00 hourly 0.9 https://trial.medpath.com/news/d0e2ce74b81965e4/biocryst-pharmaceuticals-divests-european-orladeyo-rights-for-264-million-to-achieve-debt-free-status 2025-06-27T16:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/6c88db44db4052d5/stentit-initiates-first-in-human-trial-of-regenerative-stent-for-chronic-limb-threatening-ischemia 2025-06-27T16:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/9fd1c8299ae091de/regeneron-navigates-eylea-decline-with-pipeline-diversification-and-regulatory-wins 2025-06-27T16:52:12+00:00 hourly 0.9 https://trial.medpath.com/news/090d315e1bc8f4a1/hcw-biologics-achieves-100-survival-rate-with-novel-t-cell-engagers-in-pancreatic-cancer-preclinical-study 2025-06-27T16:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/a2546ca9b962c697/fda-maintains-record-breaking-approval-pace-despite-organizational-upheaval-highlighting-three-breakthrough-therapies 2025-06-27T16:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/437c6ffb2ed3045b/swissmedic-launches-fast-track-clinical-trial-review-to-accelerate-patient-access-to-life-saving-treatments 2025-06-27T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/4a46025d88d65e93/transthera-s-tinengotinib-shows-promise-against-fgfr-resistant-cholangiocarcinoma-in-annals-of-oncology-study 2025-06-27T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/52694ab404a7bb44/schrodinger-s-sgr-1505-receives-fda-fast-track-designation-for-relapsed-waldenstrom-macroglobulinemia 2025-06-27T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/03e602e6d443c80a/bharat-biotech-and-gsk-pledge-to-cut-malaria-vaccine-price-by-more-than-half-to-under-5-by-2028 2025-06-27T15:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/595d590c39bf3029/tc-biopharm-leads-gamma-delta-t-cell-therapy-development-with-over-25-clinical-programs-worldwide 2025-06-27T15:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/1fa1f5e38c011d7d/complement-based-drug-development-gains-momentum-following-fda-approvals-and-pipeline-advances 2025-06-27T14:40:59+00:00 hourly 0.9 https://trial.medpath.com/news/eb64170ab752204d/indian-crdmos-gain-momentum-as-global-pharma-diversifies-manufacturing-operations 2025-06-27T13:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/f8dad2472ea9485b/bone-biologics-files-patent-application-for-novel-nell-1-protein-technology-in-spine-fusion 2025-06-27T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/668f2a7df2cddff5/fda-removes-regulatory-barriers-for-bristol-myers-squibb-s-car-t-cell-therapies-expanding-patient-access 2025-06-27T13:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/4274c495e983dd99/sms-pharmaceuticals-passes-second-usfda-inspection-with-zero-observations-at-telangana-analytical-laboratory 2025-06-27T13:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/1fbc0e8147db3a97/perceptive-advisors-completes-7-billion-acquisition-of-crispr-solutions-leader-synthego 2025-06-27T10:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/645026c57665a5b0/glofitamab-pirtobrutinib-combination-shows-77-response-rate-in-btk-inhibitor-exposed-mantle-cell-lymphoma 2025-06-27T09:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/c13703d443945d0b/aethlon-medical-advances-hemopurifier-cancer-trial-with-first-three-patients-treated-and-indian-regulatory-approval 2025-06-27T08:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/1f90c419684bf8b6/fda-approves-streamlined-access-for-bristol-myers-squibb-car-t-cell-therapies 2025-06-27T08:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/c7a4a6f5556fcd4a/real-world-study-reveals-significant-neutropenia-risk-variations-among-adc-therapies 2025-06-27T08:55:15+00:00 hourly 0.9 https://trial.medpath.com/news/9717086fd074a725/asahi-kasei-pharma-initiates-phase-iii-trial-of-art-123-for-chemotherapy-induced-peripheral-neuropathy-prevention 2025-06-27T08:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/0894f4767050764c/ucb-s-fenfluramine-achieves-positive-phase-3-results-in-ultra-rare-cdkl5-deficiency-disorder 2025-06-27T08:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/21ffe84a3f209731/fda-amplifies-medtronic-recall-of-bravo-acid-reflux-test-capsules-after-33-serious-injuries 2025-06-27T06:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/a049373c60e19ba6/fda-rejects-accelerated-approval-for-edgewise-s-sevasemten-in-becker-muscular-dystrophy 2025-06-27T04:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/96bde8d5b25bef4b/zenocutuzumab-achieves-30-response-rate-in-nrg1-fusion-positive-solid-tumors-receives-fda-approval 2025-06-27T04:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/2bb4ff27619fd779/orano-med-expands-texas-r-d-center-to-advance-lead-212-targeted-alpha-therapies 2025-06-27T03:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/a1a72a7165ad4f8a/sglt2-inhibitors-linked-to-increased-red-blood-cell-counts-but-no-thrombotic-risk-in-type-2-diabetes-patients 2025-06-27T03:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/4ea60b7428db06c7/machine-learning-model-achieves-96-accuracy-in-predicting-breast-cancer-treatment-related-cardiac-events 2025-06-27T02:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/ce4faaccc572c392/tilray-medical-publishes-pharmacokinetic-study-comparing-oral-and-oromucosal-cannabis-formulations 2025-06-27T00:52:49+00:00 hourly 0.9 https://trial.medpath.com/news/9a55c2997b8eca73/eva-pharma-establishes-eighth-global-office-in-hangzhou-s-biopharma-town-to-advance-cell-and-gene-therapy-innovation 2025-06-27T00:52:18+00:00 hourly 0.9 https://trial.medpath.com/news/03497345505b78ba/amgen-escalates-patent-defense-with-three-new-biosimilar-lawsuits-targeting-denosumab-competitors 2025-06-27T00:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/a82e18e3a59906e7/ai-model-neopred-predicts-lung-cancer-treatment-response-before-surgery-using-dual-phase-ct-imaging 2025-06-27T00:51:14+00:00 hourly 0.9 https://trial.medpath.com/news/bf79c06e292cc513/proqr-submits-first-clinical-trial-application-for-rna-editing-platform-with-ax-0810-targeting-cholestatic-liver-disease 2025-06-27T00:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/e17d8c747a9fc77e/phase-3-sympatico-study-shows-promising-first-line-ibrutinib-venetoclax-combination-for-older-mcl-patients 2025-06-27T00:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/bb6355421ffdc3de/first-european-patient-receives-breakthrough-treatment-for-ultra-rare-apds-immune-disorder 2025-06-27T00:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/4ffdf724e95dc78e/modus-therapeutics-secures-sek-28-3-million-in-fully-subscribed-rights-issue-to-advance-sevuparin-development 2025-06-27T00:15:59+00:00 hourly 0.9 https://trial.medpath.com/news/c8d51befbf7cd915/artelo-biosciences-secures-4-4-million-in-funding-to-advance-clinical-trials-for-cancer-and-pain-therapeutics 2025-06-27T00:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/a3421ba504ba8875/biomerica-appoints-scott-madel-as-chief-commercial-officer-to-drive-infoods-ibs-test-commercialization 2025-06-27T00:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/848b9f0926edda4e/federal-appeals-courts-uphold-medicare-drug-price-negotiation-program-against-pharmaceutical-industry-challenges 2025-06-27T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/afbf504531693da3/budget-impact-analysis-shows-revumenib-cost-neutral-for-health-plans-despite-high-specialty-drug-costs 2025-06-26T23:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/3cb5071109e50c57/prokaryotics-secures-global-rights-to-novel-gram-negative-antibiotic-potentiator-nab741 2025-06-26T22:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/c13038ddef0da361/astellas-commits-eur129-million-to-expand-irish-operations-with-focus-on-biologics-manufacturing 2025-06-26T21:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/1228a2a26505f9b6/theracosbio-partners-with-publix-to-expand-access-to-low-cost-sglt2-inhibitor-brenzavvy-for-type-2-diabetes 2025-06-26T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/1df249e7b73680fa/incyte-names-bill-meury-as-new-ceo-replacing-11-year-veteran-herve-hoppenot 2025-06-26T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/22e8ea752dd1ed3e/vertex-pharmaceuticals-launches-journavx-first-non-opioid-acute-pain-treatment-in-over-two-decades 2025-06-26T21:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/47c4f398f4a6b7a3/fda-clears-siemens-healthineers-first-virtually-helium-free-1-5t-mri-scanner 2025-06-26T20:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/d2598f878e907498/ku-medical-center-receives-31-million-nih-grant-to-expand-pediatric-clinical-trial-access-in-underserved-areas 2025-06-26T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/c6bacbe343d5aa17/tfs-healthscience-demonstrates-specialized-capabilities-in-complex-ophthalmology-trials-for-geographic-atrophy-and-dry-eye-disease 2025-06-26T20:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/f8aa53b15835fee8/longeveron-appoints-than-powell-as-chief-business-officer-to-lead-alzheimer-s-and-hlhs-program-strategy 2025-06-26T20:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/7575151cf69bf846/angel-yeast-advances-biomanufacturing-with-new-biotechnology-park-set-for-september-launch 2025-06-26T18:11:42+00:00 hourly 0.9 https://trial.medpath.com/news/d042d010b79c454f/embolization-inc-receives-fda-clearance-for-novel-nonmetal-vascular-coil-device 2025-06-26T18:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/2edc1b75e68b14cb/cellarity-initiates-phase-1-trial-of-cly-124-first-in-class-oral-therapy-for-sickle-cell-disease 2025-06-26T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/bda92f5688ae8842/altimmune-shares-plunge-60-despite-positive-mash-trial-results-as-fibrosis-endpoint-falls-short 2025-06-26T18:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/90263f4e271afafd/provectus-pv-10-immunotherapy-shows-promise-in-head-and-neck-cancer-through-novel-cell-death-mechanism 2025-06-26T17:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/efcab6eaea44d0a5/ontario-expands-public-coverage-of-xtandi-for-high-risk-prostate-cancer-patients 2025-06-26T16:55:02+00:00 hourly 0.9 https://trial.medpath.com/news/810a8c42d1415bb0/gensight-biologics-successfully-transfers-lumevoq-manufacturing-to-catalent-for-lhon-gene-therapy 2025-06-26T16:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/23f46fc504e338f7/blood-test-shows-promise-for-early-detection-of-heart-transplant-rejection-could-replace-80-of-invasive-biopsies 2025-06-26T16:54:47+00:00 hourly 0.9 https://trial.medpath.com/news/865a9c5f4ad32769/china-approves-first-once-daily-nebulized-lama-for-copd-triggering-7-5m-milestone-for-theravance 2025-06-26T16:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/5ed73942e0ad0667/lisata-s-certepetide-shows-promising-results-in-phase-2b-pancreatic-cancer-trial 2025-06-26T16:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/57b6092b3e938a7d/oxford-scientists-develop-single-shot-malaria-vaccine-using-programmable-microcapsule-technology 2025-06-26T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/ce83333b4220f3b0/alebund-s-ap301-meets-primary-endpoint-in-phase-3-trial-for-hyperphosphatemia-in-dialysis-patients 2025-06-26T16:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/7b4be7f0c62a94c2/liposomal-lipid-nanoparticles-show-enhanced-extrahepatic-mrna-delivery-and-improved-stability 2025-06-26T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/ce333f4150478d46/plus-therapeutics-prepares-cnside-diagnostics-platform-for-u-s-commercial-launch-in-second-half-2025 2025-06-26T16:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/0459e9c7333a5a17/sysmex-america-secures-fda-clearance-for-cn-6000-automated-blood-coagulation-analyzer 2025-06-26T16:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/fefab8c8edfe41fc/portable-gene-therapy-device-could-revolutionize-on-demand-personalized-medicine-for-rare-diseases 2025-06-26T16:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/ee8bcd0e3759cfb5/lipocine-initiates-phase-3-trial-for-oral-brexanolone-in-postpartum-depression 2025-06-26T16:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/c45680399ffea129/xeomin-receives-first-ever-approval-in-japan-for-chronic-sialorrhea-treatment 2025-06-26T16:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/030c3e165ad648bd/fda-approves-enhanced-labeling-for-endari-based-on-post-marketing-pharmacokinetic-data 2025-06-26T16:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/a93e26fa982ae956/imcd-acquires-trichem-to-strengthen-pharmaceutical-supply-chain-in-india-s-generic-drug-market 2025-06-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/208b54b80044b872/zyversa-therapeutics-initiates-phase-2a-trial-for-first-in-class-diabetic-kidney-disease-treatment-var-200 2025-06-26T15:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/013eef971469f843/c7-neurotomy-combined-with-speech-therapy-shows-superior-results-for-chronic-post-stroke-aphasia 2025-06-26T14:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/f31df7648468b38d/profound-therapeutics-partners-with-novartis-in-775m-cardiovascular-drug-discovery-deal 2025-06-26T12:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/55f6188deec80515/phase-3-trial-demonstrates-selumetinib-efficacy-in-adults-with-neurofibromatosis-type-1 2025-06-26T12:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/4c76d4040a958484/ovid-therapeutics-sells-ganaxolone-royalty-rights-to-immedica-pharma-for-7-million 2025-06-26T11:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/39c454395b9b759e/former-pfizer-cso-mikael-dolsten-joins-two-biotech-boards-advancing-gene-editing-and-mast-cell-therapeutics 2025-06-26T11:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/1c27405e7e4e9715/real-world-study-reveals-only-8-of-patients-continue-glp-1-obesity-treatment-after-three-years 2025-06-26T11:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/b011cf8b418eb7f8/invetech-and-aicella-form-strategic-partnership-to-integrate-ai-into-cell-therapy-manufacturing 2025-06-26T10:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/78583bb3130575a6/kymera-therapeutics-raises-250-8-million-to-advance-targeted-protein-degradation-pipeline 2025-06-26T10:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/efdb6fe48b70f756/hong-kong-establishes-independent-drug-regulatory-authority-by-end-2026-ending-reliance-on-foreign-approvals 2025-06-26T09:11:13+00:00 hourly 0.9 https://trial.medpath.com/news/010c415e6bf555b6/teva-partners-with-formycon-to-commercialize-stelara-biosimilar-fymskina-in-germany 2025-06-26T09:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/ad73c71bbe6f99fd/ambry-genetics-care-program-achieves-99-5-accuracy-in-hereditary-cancer-risk-assessment 2025-06-26T09:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/746042c088e64a4e/2-million-donation-accelerates-car-t-cell-immunotherapy-trials-for-end-stage-cancer-patients-in-canada 2025-06-26T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e412a52b430dbba/lift-biosciences-expands-u-s-operations-with-new-houston-facility-to-advance-novel-neutrophil-immunotherapy 2025-06-26T07:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/a450adc3e79885f7/updated-covid-19-vaccines-show-strong-protection-against-severe-illness-in-comprehensive-cdc-study 2025-06-26T07:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/fee3fb59c9cedc7d/bavarian-nordic-initiates-first-clinical-trials-of-mpox-vaccine-in-infants-and-pregnant-women 2025-06-26T07:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/a8c305dfe9469a08/infliximab-biosimilar-adoption-in-pediatric-ibd-reaches-42-by-2023-reveals-regional-disparities 2025-06-26T05:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/dffe98ea96e5e191/percheron-therapeutics-acquires-phase-ii-ready-anti-vista-cancer-immunotherapy-hmbd-002-in-290m-deal 2025-06-26T04:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/90a1cdf4686e1e81/biocity-s-sc0062-receives-second-breakthrough-therapy-designation-for-diabetic-kidney-disease-treatment 2025-06-26T04:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/3f84a57b80260738/neuren-pharmaceuticals-secures-us-patent-for-nnz-2591-in-pitt-hopkins-syndrome-treatment 2025-06-26T04:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/f8cc1853d5d8663c/vor-bio-secures-global-rights-to-telitacicept-in-4-billion-deal-with-remegen 2025-06-26T04:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/716f770e00e8c2c6/new-zealand-launches-world-s-first-clinical-trial-testing-thc-cbd-combination-for-canine-osteoarthritis 2025-06-26T04:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/d521637e5fbdce10/certify-raises-40m-series-b-to-transform-healthcare-provider-data-infrastructure 2025-06-26T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/93e60a99da2be878/advanced-mycosis-fungoides-treatment-requires-strategic-sequencing-of-hdac-inhibitors-and-targeted-therapies 2025-06-26T03:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/054736c8bbd02eea/alafair-biosciences-initiates-multi-center-study-of-versawrap-hydrogel-device-for-achilles-tendon-repair 2025-06-26T03:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/1074516bd1fef206/cdc-s-reconstituted-vaccine-advisory-panel-votes-to-eliminate-thimerosal-from-all-flu-vaccines 2025-06-26T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/3d4470913cecf6f1/dbv-technologies-initiates-comfort-toddlers-phase-3-study-for-viaskin-peanut-patch-in-young-children 2025-06-26T01:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/f8af1d3e178fc890/valneva-partners-with-csl-seqirus-for-exclusive-german-vaccine-distribution-deal 2025-06-26T01:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9b6d66d25867052/tme-pharma-appoints-diede-van-den-ouden-as-new-ceo-to-advance-glioblastoma-drug-development 2025-06-26T00:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/e2fbd5a4008b7f9f/cellugy-secures-eur8-1-million-eu-funding-to-scale-microplastic-alternative-for-cosmetics-industry 2025-06-26T00:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/a69abe86fda89dff/metabolics-pharma-s-ent-03-shows-promise-in-phase-1a-trial-for-obesity-and-type-2-diabetes 2025-06-25T23:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/d6c72ae31f69042b/ps7-5-million-longitude-prize-launches-to-accelerate-ai-driven-als-drug-discovery 2025-06-25T22:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/9fd0da15c2af8020/raybiotech-and-venebio-group-form-strategic-partnership-to-accelerate-drug-development-through-integrated-proteomics-and-regulatory-expertise 2025-06-25T22:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/7d5e09c339a8f08f/minerva-biotechnologies-achieves-breakthrough-in-patient-derived-stem-cell-manufacturing-for-regenerative-medicine 2025-06-25T21:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/9a8e08f17d251f97/vetigenics-initiates-first-dual-immune-checkpoint-inhibitor-trial-in-dogs-with-solid-tumors 2025-06-25T21:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/fd741476ef515fad/jiuzhou-pharma-wins-china-patent-excellence-award-for-breakthrough-synthesis-technology 2025-06-25T21:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/519e8862a6048af2/fda-approved-liquid-imatinib-formulation-addresses-critical-dosing-challenges-in-pediatric-cancer-and-dysphagia-patients 2025-06-25T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/4e10e00b67d05fc6/exousia-pro-files-patent-for-novel-exosome-loading-technology-targeting-multi-billion-dollar-therapeutic-markets 2025-06-25T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/02d9dddfa1a15721/first-in-human-ipsc-car-nk-cell-therapy-shows-promise-for-autoimmune-disease-treatment 2025-06-25T21:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/0f401a23d6cd7660/stryker-receives-fda-clearance-for-incompass-total-ankle-system-integrating-dual-platform-technologies 2025-06-25T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/f388fabf82c32b24/bryn-pharma-initiates-clinical-trial-for-dual-dose-epinephrine-nasal-spray-to-address-anaphylaxis-treatment-gaps 2025-06-25T21:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/5f764219bb04aea5/daily-aspirin-reduces-colorectal-cancer-recurrence-by-55-in-patients-with-specific-genetic-mutations 2025-06-25T18:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/fc3a038033734821/recordati-secures-exclusive-european-rights-to-cardiovascular-drug-vazkepa-in-175-million-deal-with-amarin 2025-06-25T18:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/e607243d1572f046/contineum-therapeutics-reports-positive-phase-1b-pet-trial-results-for-pipe-791-in-multiple-sclerosis-and-pulmonary-fibrosis 2025-06-25T18:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/3cb8aa9addfe39cc/opko-health-and-entera-bio-advance-first-in-class-oral-dual-glp-1-glucagon-tablet-for-obesity-treatment 2025-06-25T18:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/32bbc493a6694b76/acadia-pharmaceuticals-unveils-12-billion-pipeline-strategy-at-inaugural-r-d-day 2025-06-25T16:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/23127ce7ffaca6da/q32-bio-names-adrien-sipos-as-interim-cmo-to-lead-alopecia-areata-drug-development 2025-06-25T16:46:17+00:00 hourly 0.9 https://trial.medpath.com/news/513bc9720ea7b846/arbutus-reacquires-global-rights-to-hepatitis-b-rnai-therapy-after-achieving-functional-cure-in-eight-patients 2025-06-25T16:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/ad6a617ffdc4fa83/dicot-pharma-completes-enrollment-in-phase-2a-erectile-dysfunction-trial-results-expected-by-november-2025 2025-06-25T16:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/7e6db5dc4bf9e235/assembly-biosciences-abi-4334-shows-potent-antiviral-activity-in-phase-1b-chronic-hepatitis-b-trial 2025-06-25T16:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/39155a14d7f8439a/mira-pharmaceuticals-unveils-preclinical-data-for-skny-1-targeting-obesity-and-smoking-cessation-without-cns-side-effects 2025-06-25T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/149433a986ae159a/lupin-partners-with-sino-universal-pharmaceuticals-to-commercialize-tiotropium-dpi-for-copd-treatment-in-china 2025-06-25T16:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/8a76952318bde80a/evaxion-launches-ai-powered-vaccine-program-against-group-a-streptococcus 2025-06-25T16:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/c6fd6212df95d689/fda-grants-rmat-designation-to-detalimogene-for-high-risk-bladder-cancer 2025-06-25T16:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/540a76e4eafbb8a9/angel-pharmaceuticals-receives-china-ind-approval-for-soquelitinib-atopic-dermatitis-trial 2025-06-25T16:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/13f4aa57209c3fea/sanofi-advances-kymera-s-next-generation-irak4-degrader-kt-485-to-clinical-testing 2025-06-25T16:30:37+00:00 hourly 0.9 https://trial.medpath.com/news/06bba25d7d546ae4/gilead-and-kymera-partner-on-novel-cdk2-molecular-glue-degrader-for-cancer-treatment 2025-06-25T16:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/fbba8903c278b110/bio-thera-solutions-initiates-phase-3-trial-for-bat8006-adc-in-platinum-resistant-ovarian-cancer 2025-06-25T16:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/1c564251dee48840/hamlet-biopharma-receives-fda-clearance-for-phase-iii-bladder-cancer-trial-following-successful-regulatory-meeting 2025-06-25T16:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/ff2bb25cdccabfff/fraunhofer-researchers-develop-breakthrough-method-to-measure-lung-drug-levels-through-exhaled-breath-particles 2025-06-25T16:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/5fe99f98399bf50d/femasys-receives-world-s-first-regulatory-approval-for-non-surgical-permanent-birth-control-system-in-europe 2025-06-25T16:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/d4d5a5d3ac0a42b3/minovia-therapeutics-announces-180m-spac-merger-to-advance-first-in-class-mitochondrial-therapy-platform 2025-06-25T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/388d08f42f7a058b/hoth-therapeutics-and-silo-pharma-form-joint-venture-to-develop-va-licensed-gdnf-based-obesity-treatment 2025-06-25T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/f6f6f0ddac650803/oral-sulopenem-shows-non-inferiority-to-standard-care-in-phase-3-trial-for-uncomplicated-utis 2025-06-25T16:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/206b604a432637df/breye-therapeutics-completes-phase-1b-trial-of-oral-danegaptide-for-early-stage-diabetic-retinopathy 2025-06-25T16:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/8a1c7dc1a09f0491/empatica-launches-world-s-smallest-clinical-trial-wearable-device-for-digital-biomarker-collection 2025-06-25T16:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/92b3c196cb13974a/botulinum-toxin-combination-therapy-reduces-salivary-gland-toxicity-in-psma-radioligand-treatment 2025-06-25T15:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/2656ea4ea9bc5fa0/plus-therapeutics-restructures-15-million-equity-financing-to-eliminate-potential-1-5-billion-share-dilution 2025-06-25T14:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/7d49456c25634a12/qbiotics-tigilanol-tiglate-achieves-80-response-rate-in-soft-tissue-sarcoma-phase-iia-trial 2025-06-25T12:52:57+00:00 hourly 0.9 https://trial.medpath.com/news/90f85dafd52f375c/tgfb2-gene-methylation-identified-as-positive-prognostic-biomarker-for-pancreatic-cancer 2025-06-25T12:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/9c682964567d7e1d/biogen-advances-salanersen-to-phase-3-studies-for-spinal-muscular-atrophy-after-promising-results 2025-06-25T12:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/4e445280fb449520/metastx-receives-nci-grant-to-develop-ai-powered-diagnostic-for-metastatic-prostate-cancer-prediction 2025-06-25T12:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/649e1e5531162909/adipose-derived-stem-cell-therapy-achieves-100-hair-regrowth-in-male-mice-for-androgenetic-alopecia 2025-06-25T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9260f35653617327/scancell-initiates-intradermal-dosing-in-phase-2-melanoma-trial-reports-strong-early-efficacy-data 2025-06-25T08:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/ae671848b99b7d6a/sun-pharma-s-european-partner-withdraws-melanoma-therapy-application-from-ema-due-to-data-delays 2025-06-25T08:51:28+00:00 hourly 0.9 https://trial.medpath.com/news/db5696f6de48dcad/valorum-biologics-secures-exclusive-rights-to-commercialize-formycon-s-eylea-biosimilar-in-north-america 2025-06-25T08:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/f7b33c7a9cb22054/circulating-tumor-dna-testing-transforms-breast-cancer-monitoring-and-treatment-selection 2025-06-25T08:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/196c3c39c6751b6a/galderma-launches-phase-ii-trials-of-nemolizumab-for-systemic-sclerosis-and-chronic-pruritus-of-unknown-origin 2025-06-25T08:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/fd65b98a418b8d9b/lts-and-nualtis-form-strategic-partnership-to-scale-oral-thin-film-drug-delivery-manufacturing 2025-06-25T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/203220d9acc8896f/evotec-joins-nurture-aki-consortium-to-advance-multi-omics-research-for-acute-kidney-injury-treatment 2025-06-25T07:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/1abfe1508e149243/vcu-researchers-develop-fusion-superkine-therapy-for-glioblastoma-with-novel-blood-brain-barrier-delivery-system 2025-06-25T06:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/81a072d855a5977a/civicascript-launches-low-cost-generic-dimethyl-fumarate-for-multiple-sclerosis-treatment 2025-06-25T06:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/97469c0a5cba3a5a/liminatus-pharma-advances-second-generation-cd47-inhibitor-iba101-toward-2027-clinical-trials 2025-06-25T06:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/740d67375659141e/clinicians-develop-new-monitoring-strategies-for-hypercortisolism-medical-management 2025-06-25T05:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/ba6cce770b0da614/zetroz-systems-sam-r-2-0-wearable-ultrasound-device-receives-arthritis-foundation-s-ease-of-use-certification 2025-06-25T03:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/4c5a274a490da9cf/extended-imatinib-therapy-shows-promise-in-high-risk-gist-patients-as-novel-agents-enter-clinical-development 2025-06-25T03:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/f3da36d3298c2a81/bracelet-1-trial-shows-promise-for-oncolytic-virus-pelareorep-in-hr-breast-cancer 2025-06-25T02:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/570c49b3e1d0435d/cue-biopharma-receives-positive-fda-feedback-for-cue-401-autoimmune-therapy-advances-toward-ind-filing 2025-06-25T01:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/22cbc725418c3aaa/nhs-delivers-first-brain-infused-gene-therapy-for-rare-aadc-deficiency-showing-promising-results-in-three-year-old-patient 2025-06-25T01:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/ca5778db64759acb/eli-lilly-s-olomorasib-receives-fda-orphan-drug-designation-for-kras-g12c-mutated-nsclc-treatment 2025-06-25T01:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/9f93a067716d1d86/trem2-emerges-as-dual-regulator-of-lipid-metabolism-and-immune-response-in-mash 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/881096a7ac9e9f6f/guselkumab-demonstrates-high-efficacy-for-psoriasis-treatment-across-all-skin-tones-in-landmark-visible-trial 2025-06-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f521226be2ac57b4/liquidia-secures-50-million-funding-following-yutrepia-commercial-launch-and-legal-victory 2025-06-24T22:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/a76a26b2e0175c6e/fortrea-and-emery-pharma-partner-to-enable-fda-compliant-rifampin-use-in-drug-drug-interaction-studies 2025-06-24T22:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/282b3beae5ac4d6d/pathpresenter-receives-fda-510-k-clearance-for-digital-pathology-clinical-viewer 2025-06-24T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/78754cded6028205/cigna-sues-bristol-myers-squibb-over-alleged-monopoly-practices-for-cancer-drug-pomalyst 2025-06-24T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/afbbf6376e548cc7/trinity-biotech-receives-who-approval-for-offshore-manufacturing-of-hiv-rapid-test 2025-06-24T21:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/c328d19db5c62a33/phase-3-trial-shows-olanzapine-significantly-reduces-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients 2025-06-24T20:17:10+00:00 hourly 0.9 https://trial.medpath.com/news/30d16518ad27fd81/curiteva-receives-fda-510-k-clearance-for-first-3d-printed-peek-standalone-spinal-implant 2025-06-24T20:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/9f7a8ba2aca24ea1/breckenridge-pharmaceutical-receives-fda-approval-for-generic-dehydrated-alcohol-injection-for-hypertrophic-obstructive-cardiomyopathy 2025-06-24T20:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/7d4fcc1e9943948c/duvelisib-romidepsin-combination-shows-61-response-rate-in-relapsed-t-cell-lymphomas 2025-06-24T20:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/7af8c52ba713b093/tirzepatide-shows-promise-for-type-1-diabetes-in-off-label-use-study 2025-06-24T20:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/75a5bbf6d66145cc/forsight-robotics-raises-125m-series-b-to-advance-oryom-robotic-eye-surgery-platform 2025-06-24T18:51:53+00:00 hourly 0.9 https://trial.medpath.com/news/5389801f868a20b7/abridge-secures-300m-series-e-funding-reaches-5-3b-valuation-for-ai-clinical-documentation-platform 2025-06-24T18:50:59+00:00 hourly 0.9 https://trial.medpath.com/news/4f4b41894f96f701/inventprise-s-novel-covid-19-conjugate-vaccine-shows-broad-protection-against-multiple-variants-in-preclinical-study 2025-06-24T18:09:34+00:00 hourly 0.9 https://trial.medpath.com/news/86eda9fec4950ddf/xenon-pharmaceuticals-appoints-darren-cline-as-chief-commercial-officer-ahead-of-azetukalner-phase-3-data 2025-06-24T18:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/ac0752565fb6f666/biocon-biologics-partners-with-malaysia-s-national-cancer-society-to-launch-biosimilar-access-program 2025-06-24T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf8ada8730ba2707/starton-therapeutics-partners-with-bend-bioscience-to-develop-oral-sustained-release-lenalidomide-for-multiple-myeloma 2025-06-24T17:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/e6c0313284b2bb33/nct-ucc-dresden-launches-phase-2-trial-of-personalized-mrna-vaccine-for-pancreatic-cancer 2025-06-24T17:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/34e52b25e28bb0da/priothera-secures-eur1-7-million-government-funding-to-enhance-car-t-cell-therapy-with-novel-s1p-receptor-modulator 2025-06-24T17:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/35c55a46b497e2a6/astrazeneca-faces-patent-challenges-for-diabetes-drug-as-sandoz-seeks-revocation 2025-06-24T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/08633d4f38311fc8/vector-biomed-partners-with-indian-cancer-hospital-to-deliver-affordable-car-t-therapy-to-rural-populations 2025-06-24T17:12:38+00:00 hourly 0.9 https://trial.medpath.com/news/5882a2ee64c41e55/cellectar-biosciences-submits-phase-1b-protocol-for-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-06-24T17:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/84609b5435e2ae8f/rivus-pharmaceuticals-hu6-demonstrates-significant-liver-fat-reduction-in-phase-2-mash-trial 2025-06-24T17:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/3c66b18acb2ddde7/biomarin-s-roctavian-gene-therapy-shows-sustained-efficacy-after-five-years-in-severe-hemophilia-a 2025-06-24T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/27470d5f3533cefe/favipiravir-shows-promise-against-deadly-chandipura-virus-in-preclinical-studies 2025-06-24T17:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/f37683d27aacd8ff/enhanced-genomics-partners-with-alborada-institute-to-accelerate-alzheimer-s-drug-discovery-using-3d-multi-omics-platform 2025-06-24T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/acc3b79b3cc40f97/mindrank-s-ai-designed-oral-glp-1-drug-achieves-10-3-weight-loss-in-phase-2b-trial 2025-06-24T16:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/0abae5b5c21ee6c7/neuron23-secures-96-5m-series-d-funding-as-first-patient-dosed-in-phase-2-parkinson-s-disease-trial 2025-06-24T16:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/98fb1040795e1218/maia-biotechnology-expands-scientific-advisory-board-with-hcc-experts-as-phase-2-trial-approaches 2025-06-24T16:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/7bf60f8968d69db1/cytodyn-initiates-phase-ii-trial-of-leronlimab-in-relapsed-refractory-colorectal-cancer 2025-06-24T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/2cb9d7944985caf1/inmed-s-inm-901-shows-significant-anti-inflammatory-activity-in-alzheimer-s-disease-preclinical-study 2025-06-24T16:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/8b68a6b9c8abdb04/stuart-therapeutics-reports-mixed-phase-iii-results-for-st-100-dry-eye-treatment 2025-06-24T16:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/d90745fdc22f399b/smart-soft-healthcare-s-columbo-ai-spine-assistant-receives-fda-clearance-for-enhanced-scoliosis-and-fracture-detection 2025-06-24T16:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/ca1c062b8f43c277/jb-chemicals-secures-fda-approval-for-generic-amitriptyline-depression-treatment 2025-06-24T16:14:20+00:00 hourly 0.9 https://trial.medpath.com/news/05c80149c4fdee49/kif18a-emerges-as-promising-cancer-target-with-multiple-therapies-advancing-through-clinical-trials 2025-06-24T16:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/4123fa21908ba6dc/world-s-first-bioengineered-external-liver-assist-device-treats-patient-in-groundbreaking-clinical-trial 2025-06-24T16:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/73518d3888b3defb/krystal-biotech-initiates-phase-3-trial-of-kb803-gene-therapy-for-corneal-complications-in-dystrophic-epidermolysis-bullosa 2025-06-24T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/e3ec130711582e2c/supercede-therapeutics-reports-promising-preclinical-data-for-novel-oral-obesity-treatment-targeting-actrii-pathway 2025-06-24T15:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/47942d54df6ff4c2/schott-pharma-commits-eur100-million-to-expand-ready-to-use-sterile-cartridge-manufacturing 2025-06-24T13:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/ca1d904d6717790e/imdx-digital-pcr-platform-shows-equivalent-performance-to-ngs-in-kidney-transplant-rejection-testing 2025-06-24T13:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/e6f6037d7a368bf5/bio-techne-partners-with-usp-to-enhance-quality-standards-for-monoclonal-antibody-and-gene-therapy-development 2025-06-24T13:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/f78cf5f50fd7dea4/outsee-secures-ps1-8m-seed-funding-to-advance-ai-powered-genomics-platform-for-drug-discovery 2025-06-24T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/bec51e77408b2d3c/sterotherapeutics-doses-first-patient-in-phase-2-trial-of-st-002-for-cushing-s-syndrome 2025-06-24T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/eca94a6d2fd9f1a1/bayer-extends-16-year-research-partnership-with-tsinghua-university-for-three-more-years 2025-06-24T13:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/407a3513df2fcd1b/revolution-medicines-secures-2-billion-funding-deal-with-royalty-pharma-for-ras-cancer-drug-development 2025-06-24T13:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/f4f08f1083bd0969/brightgene-s-dual-glp-1r-gipr-agonist-bgm0504-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trial 2025-06-24T12:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/9cbc9ac9b45944f7/sonrai-analytics-partners-with-plectonic-biotech-to-advance-ai-driven-logic-gated-antibody-cancer-immunotherapies 2025-06-24T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/544a7ae3a0cdec7e/glenmark-launches-tevimbra-first-immuno-oncology-drug-in-india-for-lung-and-esophageal-cancer-treatment 2025-06-24T12:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/4c166213c691566c/zambon-secures-chinese-approval-for-intravenous-fluimucil-following-successful-phase-3-trial 2025-06-24T12:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/0ffac2adde9bd5a7/australian-clinical-trials-test-antiviral-drugs-targeting-epstein-barr-virus-for-multiple-sclerosis-treatment 2025-06-24T12:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/d24597931fe24ae9/lundbeck-s-lu-ag13909-receives-orphan-drug-designation-for-congenital-adrenal-hyperplasia-treatment 2025-06-24T09:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/c684f4abe57440d6/her2-positive-gastric-cancer-pipeline-shows-robust-activity-with-20-companies-developing-novel-therapies 2025-06-24T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/69b8746fdcb38107/axcelead-ddp-and-superluminal-expand-partnership-to-target-challenging-biological-mechanisms 2025-06-24T05:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/ea8968b262159acb/ema-backs-ozempic-label-expansion-for-peripheral-artery-disease-based-on-stride-trial-data 2025-06-24T05:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/f48bb536c87df93b/deepecho-receives-fda-510-k-clearance-for-ai-powered-fetal-ultrasound-analysis-platform 2025-06-24T04:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/0d56903a3b8c1c33/tissium-receives-fda-de-novo-authorization-for-first-atraumatic-sutureless-peripheral-nerve-repair-system 2025-06-24T04:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/a3a5e4d6f957f0c1/psychedelic-therapy-expands-beyond-cancer-care-as-multi-center-studies-launch 2025-06-24T03:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/70677e292663166b/quanterix-receives-south-korean-approval-for-alzheimer-s-biomarker-detection-platform 2025-06-24T03:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/2bd3316709ddf43c/implantica-completes-fda-pma-submission-for-refluxstop-device-prepares-us-manufacturing-for-gerd-treatment 2025-06-24T02:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5eb91c57982feb6/cambridge-healthcare-innovations-unveils-quattrii-inhaler-technology-to-deliver-large-dose-biologics-and-mrna-therapies 2025-06-24T01:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/d93bafae4df0bf0a/nektar-therapeutics-to-report-phase-2b-atopic-dermatitis-trial-results-for-novel-regulatory-t-cell-therapy 2025-06-24T01:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/76c778926e93471a/nuvalent-to-present-pivotal-data-for-ros1-selective-inhibitor-zidesamtinib-in-advanced-lung-cancer 2025-06-24T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/ed9dbcbdfe6a8aa1/ibio-advances-ai-driven-obesity-pipeline-with-myostatin-and-activin-e-antibody-therapies 2025-06-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/f4876d4db1103dfe/sanofi-invests-25-million-in-adagene-s-safebody-platform-for-next-generation-cancer-immunotherapy 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/734975d61bfb3394/pathai-receives-fda-clearance-for-aisight-dx-digital-pathology-platform-for-primary-diagnosis 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9e870e76e926bafe/ftc-and-doj-complete-final-listening-session-on-drug-price-competition-reforms 2025-06-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b1c0bcb05bdfe119/tam-global-appoints-leading-cancer-immunologist-dr-francesco-marincola-as-chief-scientific-officer 2025-06-23T23:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/0e5752e895a56221/fda-s-acting-drug-chief-jacqueline-corrigan-curay-to-retire-amid-leadership-exodus 2025-06-23T22:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/b6a84da5930cf1da/australian-government-invests-12-million-in-cardiovascular-and-diabetes-medical-technology-innovation 2025-06-23T22:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/dc035eaeb139067e/sichuan-biokin-s-first-in-class-egfr-her3-adc-advances-to-phase-3-trials-across-multiple-cancer-types 2025-06-23T21:43:33+00:00 hourly 0.9 https://trial.medpath.com/news/dd832d165b255bc0/illumina-acquires-somalogic-for-425-million-to-accelerate-proteomics-and-multiomics-strategy 2025-06-23T21:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/5d7bd56da62ae0f7/dr-ashleys-limited-acquires-impact-biomedical-in-strategic-reverse-merger-to-accelerate-global-drug-development 2025-06-23T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/09cdcece021e9419/lifeplus-achieves-clinical-validation-for-revolutionary-non-invasive-glucose-and-blood-pressure-monitoring-device 2025-06-23T21:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/3175af6090e49ec1/crispr-base-editing-shows-promise-for-treating-fatal-pediatric-vascular-disease-msmds 2025-06-23T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/dd3a9456a20a3ff0/candel-therapeutics-names-charles-schoch-as-permanent-cfo-following-successful-86m-capital-raise 2025-06-23T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/cc3bd341f16fa3f7/biostem-technologies-completes-enrollment-in-diabetic-foot-ulcer-trial-testing-placental-derived-allograft 2025-06-23T20:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/46523912e8911988/evofem-s-phexxi-hormone-free-contraceptive-seeks-regulatory-approval-in-uae-through-strategic-partnership 2025-06-23T20:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/e7e1dd6d396b6ddc/oxford-biomedica-achieves-full-ownership-of-us-subsidiary-to-strengthen-global-gene-therapy-manufacturing-network 2025-06-23T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/23c6d50e1a955d69/nccn-guidelines-lag-behind-clinical-practice-as-oncologists-increasingly-adopt-ctdna-testing 2025-06-23T18:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/2affd09c3876e494/laekna-s-lae102-shows-promising-safety-profile-in-first-in-human-obesity-trial-at-ada-2025 2025-06-23T17:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/ab09e50529ac2192/lexaria-bioscience-reaches-50-patent-milestone-with-new-epilepsy-and-nicotine-delivery-patents 2025-06-23T16:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/6842f346cd600c00/carisma-therapeutics-and-orthocellix-announce-25m-merger-to-advance-phase-3-knee-cartilage-therapy 2025-06-23T16:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/ec69050834ff4374/cure-rare-disease-advances-lgmdr9-gene-therapy-following-positive-fda-pre-ind-meeting 2025-06-23T16:55:05+00:00 hourly 0.9 https://trial.medpath.com/news/5c191dca6fe80e67/fujirebio-acquires-plasma-services-group-to-strengthen-rare-disease-biomarker-supply-chain 2025-06-23T16:55:01+00:00 hourly 0.9 https://trial.medpath.com/news/2e9fed5171aaee39/arcturus-therapeutics-to-present-phase-2-data-for-arct-810-mrna-therapy-in-rare-genetic-disorder 2025-06-23T16:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/7c2254f24e625abe/sanofi-licenses-dual-jak-syk-inhibitor-gusacitinib-from-formation-bio-in-eur545-million-deal 2025-06-23T16:50:27+00:00 hourly 0.9 https://trial.medpath.com/news/96cfbf11193df717/cumberland-pharmaceuticals-reports-positive-phase-2-results-for-ifetroban-in-duchenne-muscular-dystrophy-heart-disease 2025-06-23T16:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/58b8034a1501a164/oryzon-submits-phase-iii-protocol-for-vafidemstat-in-borderline-personality-disorder-targeting-first-fda-approved-treatment 2025-06-23T16:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/e62ad3e3373cee94/denovo-biopharma-out-licenses-biomarker-guided-depression-drug-db104-to-taiwan-partner 2025-06-23T16:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/562eac036192164e/viromed-s-cold-plasma-technology-demonstrates-potential-to-prevent-6000-deaths-annually-from-ventilator-associated-pneumonia 2025-06-23T16:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/1b5640c848670ce2/fda-approves-first-bone-growth-accelerator-for-spinal-fusion-surgery 2025-06-23T16:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/a86f9212973a7192/vsee-health-selected-for-nih-funded-phase-3-stroke-telerehabilitation-trial-across-29-hospitals 2025-06-23T16:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/3c9e032f6ffd642e/angiodynamics-initiates-recover-av-trial-for-pulmonary-embolism-treatment-device 2025-06-23T16:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/acf39b8119e34807/altrubio-s-altb-268-shows-promise-in-preclinical-models-of-inflammatory-diseases-supporting-phase-2-uc-trial 2025-06-23T15:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/8123ce5d8de67de4/new-analysis-shows-radicava-ors-extends-survival-and-slows-functional-decline-in-als-patients 2025-06-23T13:39:58+00:00 hourly 0.9 https://trial.medpath.com/news/0a2ec30bd8661003/personalized-treatment-strategies-and-adverse-event-management-transform-mcrpc-care 2025-06-23T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/a2190c0b05f3f20a/monument-therapeutics-reports-positive-phase-i-results-for-novel-schizophrenia-cognitive-treatment-mt1988 2025-06-23T13:17:35+00:00 hourly 0.9 https://trial.medpath.com/news/7d00187fbd42ee54/penn-researchers-transform-deadly-aspergillus-fungus-into-potent-anti-leukemia-drug 2025-06-23T13:14:26+00:00 hourly 0.9 https://trial.medpath.com/news/bdb75d126f5292b9/mbx-biosciences-strengthens-leadership-with-endocrinology-expert-to-advance-hypoparathyroidism-treatment 2025-06-23T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/c840bc3e9d9316fb/biomea-fusion-s-icovamenib-shows-promise-in-combination-with-glp-1-therapies-for-type-2-diabetes 2025-06-23T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/d4257440f825d21d/itm-and-debiopharm-initiate-new-study-arm-for-caix-targeted-theranostic-in-clear-cell-renal-cell-carcinoma 2025-06-23T13:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/626a154c46a58a63/immutep-s-imp761-shows-80-t-cell-suppression-in-phase-i-autoimmune-disease-trial 2025-06-23T13:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/2f77a05c074020ce/novadip-receives-fda-rmat-designation-for-nvd003-regenerative-therapy-in-rare-pediatric-bone-disease 2025-06-23T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/c411e6fd684563b4/spanish-researchers-develop-dna-test-to-predict-chemotherapy-resistance-clinical-trials-set-for-2026 2025-06-23T13:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/0df13e8effd942f1/ema-recommends-approval-of-alvotech-s-biosimilar-to-eylea-for-eye-disorders 2025-06-23T13:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/52c22dbd7f3319b4/clinuvel-ceo-returns-to-drive-us-expansion-with-vitiligo-treatment-approval-strategy 2025-06-23T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/60914d5573b4b67a/bionxt-launches-feasibility-study-for-oral-dissolvable-film-semaglutide-delivery 2025-06-23T13:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/92283fc7c5c88244/united-therapeutics-completes-enrollment-of-phase-3-trial-for-once-daily-oral-pah-treatment-ralinepag 2025-06-23T13:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/ef9898dcf6a99291/vertex-and-ono-pharmaceutical-form-strategic-alliance-for-povetacicept-development-in-japan-and-south-korea 2025-06-23T13:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/02f7e4da992949f5/idorsia-s-quviviq-receives-approval-in-china-for-insomnia-treatment-through-simcere-partnership 2025-06-23T10:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/fd568b9d73e22d05/progenis-pharmaceuticals-secures-mtpconnect-funding-for-novel-rna-based-type-2-diabetes-treatment 2025-06-23T08:55:42+00:00 hourly 0.9 https://trial.medpath.com/news/556ad0d43762d9db/carmil2-gain-of-function-mutation-shows-promise-for-next-generation-cancer-immunotherapies 2025-06-23T08:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/17d5ee73e006101a/roche-s-nxt007-achieves-zero-bleeds-in-phase-i-ii-hemophilia-a-trial-advances-to-phase-iii 2025-06-23T08:54:46+00:00 hourly 0.9 https://trial.medpath.com/news/f63143c98bb40b8c/galapagos-appoints-former-horizon-cfo-aaron-cox-to-lead-strategic-transformation 2025-06-23T08:54:24+00:00 hourly 0.9 https://trial.medpath.com/news/65791d290a1315cc/utopia-therapeutics-secures-1-5m-for-novel-obesity-vaccine-ut009 2025-06-23T08:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/ad1ee198145795b2/primary-biliary-cholangitis-pipeline-shows-strong-progress-with-multiple-late-stage-therapies-and-recent-fda-approvals 2025-06-23T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/8e45e8b18cb445f6/otsuka-pharmaceutical-secures-global-rights-to-hbm7020-bcmaxcd3-bispecific-t-cell-engager-for-autoimmune-diseases 2025-06-23T05:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/fa35ce8a8d2c1531/water-consumption-doubles-diabetes-remission-rates-compared-to-diet-beverages-in-clinical-study 2025-06-23T05:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/84afce926726b204/xtalpi-secures-100-million-partnership-with-harvard-s-gregory-verdine-to-advance-ai-driven-drug-discovery 2025-06-23T04:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/cb5d595df196ed6c/major-food-companies-eliminate-artificial-dyes-following-fda-push-and-health-concerns 2025-06-23T04:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/0c3b2f635715743d/proteomics-international-launches-next-generation-promarkerd-test-for-early-diabetic-kidney-disease-detection-in-us-market 2025-06-23T00:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/9c07ea3524d074b8/biotech-industry-faces-wave-of-strategic-layoffs-as-companies-prioritize-efficiency-and-pipeline-focus 2025-06-23T00:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/71951524367dd24e/sonrotoclax-plus-zanubrutinib-shows-promise-in-relapsed-refractory-mantle-cell-lymphoma-with-78-response-rate 2025-06-22T21:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/5750243854db95c9/novo-nordisk-s-mim8-shows-safe-direct-switch-from-emicizumab-in-phase-3b-hemophilia-a-trial 2025-06-22T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/b1f2c5e3d96e6973/lilly-s-once-weekly-insulin-efsitora-alfa-achieves-non-inferiority-in-phase-3-trials-reducing-injection-burden-by-300-doses-annually 2025-06-22T20:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/bb8f5523eaf4504d/russia-initiates-phase-i-clinical-trial-for-enteromix-cancer-vaccine-based-on-four-non-pathogenic-viruses 2025-06-22T17:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/e652017036d4545c/eli-lilly-s-oral-diabetes-drug-orforglipron-shows-promise-in-phase-3-trial-offering-alternative-to-injectable-glp-1-therapies 2025-06-22T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/4f3431eeaf44e1eb/japanese-startup-s-urine-based-cancer-test-detects-stage-0-lung-cancer-in-hokkaido-pilot-study 2025-06-22T04:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/1a30975af9c15491/magellan-stem-cells-receives-tga-manufacturing-license-advancing-australia-s-cell-therapy-independence 2025-06-22T04:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/e95de06cdba56a6c/fda-approves-lenacapavir-for-hiv-prevention-with-99-9-efficacy-but-high-cost-raises-accessibility-concerns-in-india 2025-06-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/7fa62ce1cc657cf8/researchers-advance-nanoscale-drug-delivery-systems-with-targeted-cell-recognition-and-biological-signal-response 2025-06-22T01:03:32+00:00 hourly 0.9 https://trial.medpath.com/news/e3ec19f6114bd70c/abvance-therapeutics-presents-first-human-data-on-fixed-ratio-insulin-glucagon-combination-for-type-1-diabetes 2025-06-22T01:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/d52e5a013db89bd2/novartis-kesimpta-shows-sustained-efficacy-in-multiple-sclerosis-patients-over-seven-years 2025-06-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c0b4ff72d4e3cda/novel-radioligand-therapy-177lu-lu-neob-enters-clinical-testing-for-advanced-breast-cancer 2025-06-21T23:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/e15674f780792854/sai-life-sciences-completes-major-capacity-expansion-at-bidar-manufacturing-facility 2025-06-21T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/724a895bf4f98958/novel-drug-delivery-technology-aims-to-prevent-opioid-overdoses-through-controlled-release 2025-06-21T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/8c4e87b23337e619/lundbeck-s-eptinezumab-shows-strong-efficacy-in-asian-chronic-migraine-patients-in-phase-iii-sunrise-trial 2025-06-21T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/bbe1bb855839257d/unc-lineberger-cancer-center-leads-28-million-arpa-h-trial-to-revolutionize-metastatic-breast-cancer-treatment 2025-06-21T14:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/5f640697f8031980/gan-lee-s-bofanglutide-shows-superior-efficacy-to-semaglutide-in-phase-2-diabetes-trials 2025-06-21T13:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/bb0e2d4acad1673e/medtronic-s-minimed-780g-system-shows-promise-for-type-2-diabetes-and-young-children-with-type-1-diabetes 2025-06-21T06:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/99106e5bdf8e69a0/verdiva-bio-advances-once-weekly-oral-glp-1-and-amylin-therapies-for-obesity-treatment 2025-06-21T05:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/db99b03c226ffdf5/oncology-pharmacists-demonstrate-significant-cost-savings-and-expanded-clinical-roles-through-remote-services-and-ai-integration 2025-06-21T03:09:03+00:00 hourly 0.9 https://trial.medpath.com/news/2fd89078feb18157/ema-initiates-review-of-sodium-oxybate-for-alcohol-dependence-following-efficacy-and-safety-concerns 2025-06-21T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/15488da4586af394/phase-2-trial-shows-promising-survival-rates-for-stem-cell-transplants-from-mismatched-unrelated-donors 2025-06-21T00:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/6b562bacacd465cb/pharmala-files-c-50-million-shelf-prospectus-to-advance-mdma-drug-development 2025-06-21T00:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/e62e15b0faff5a9f/glp-1-diabetes-drug-liraglutide-reduces-migraine-days-by-half-in-pilot-study 2025-06-21T00:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/efd8a0f816ed8b62/cansinobio-launches-ipneucia-r-13-valent-pneumococcal-vaccine-optimized-for-chinese-children 2025-06-20T22:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/67fcf1d5d26be454/regeneron-expands-patent-protection-for-aflibercept-with-new-formulation-patent-against-amgen 2025-06-20T21:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/8438b7ba625725f0/gh-research-submits-ind-hold-response-to-fda-for-depression-treatment-gh001-ahead-of-schedule 2025-06-20T21:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/c3f1c3093ca123b0/cereno-scientific-secures-100-msek-financing-to-advance-hdac-inhibitor-pipeline-for-rare-cardiovascular-and-pulmonary-diseases 2025-06-20T19:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/8e93ac1610483782/aurobindo-pharma-secures-multiple-fda-approvals-for-generic-drug-portfolio-expansion 2025-06-20T18:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/c4a37b9f81a881f5/candid-therapeutics-doses-first-patients-with-novel-t-cell-engagers-for-autoimmune-diseases 2025-06-20T18:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/0fbc3f0cf5560f44/dutch-court-upholds-xtandi-patent-protection-blocking-generic-enzalutamide-launch-until-2028 2025-06-20T16:56:18+00:00 hourly 0.9 https://trial.medpath.com/news/0acb9dfeade9328f/terumo-bct-unveils-automated-car-t-manufacturing-platform-delivering-12-billion-cells-in-7-8-days 2025-06-20T16:56:09+00:00 hourly 0.9 https://trial.medpath.com/news/3817c89ff2bfd8c0/lomond-therapeutics-receives-fda-clearance-for-phase-1-trial-of-lonitoclax-in-relapsed-refractory-aml 2025-06-20T16:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/0016a785351f2f83/bio-thera-solutions-receives-positive-chmp-opinion-for-ustekinumab-biosimilar-usymro 2025-06-20T16:53:39+00:00 hourly 0.9 https://trial.medpath.com/news/28f7cfb1b560904b/moleculin-biotech-raises-5-9-million-to-advance-annamycin-through-phase-3-aml-trial 2025-06-20T16:52:23+00:00 hourly 0.9 https://trial.medpath.com/news/24e02bdbe944ef72/onco360-partners-with-deciphera-to-distribute-qinlock-for-advanced-gist-patients 2025-06-20T16:14:58+00:00 hourly 0.9 https://trial.medpath.com/news/ee5e1d0abe93f98c/perceptive-discovery-and-pfizer-launch-fibre-consortium-to-advance-fibrosis-drug-development-through-advanced-imaging 2025-06-20T16:14:43+00:00 hourly 0.9 https://trial.medpath.com/news/360f565258d19fc5/shine-technologies-lutetium-177-isotope-ilumira-reaches-global-milestone-with-19-country-distribution-network 2025-06-20T16:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/92bdcb8f48a7085e/european-medicines-agency-recommends-approval-of-partner-therapeutics-imreplys-for-acute-radiation-syndrome-treatment 2025-06-20T16:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/e5392dd4a64d7ea6/bridge-biotherapeutics-pivots-to-bitcoin-treasury-strategy-following-clinical-trial-failures 2025-06-20T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/b79f04014486dc38/immuno-cure-partners-with-pharmajet-to-advance-hiv-therapeutic-dna-vaccine-using-needle-free-delivery-technology 2025-06-20T15:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/942cea2b15b5b52a/valirx-secures-ps16-million-licensing-deal-for-repurposed-risperidone-cancer-therapy-val401 2025-06-20T14:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/e21b1a1a0d5fff7a/european-phase-ii-trial-tests-simple-home-intervention-to-prevent-heart-failure-in-cancer-survivors 2025-06-20T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/5a3c66c9f42e3bef/researchers-develop-first-risk-prediction-model-for-early-stage-hodgkin-s-lymphoma 2025-06-20T10:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/997585e9f6b8e0a9/altum-sequencing-s-liquid-biopsy-technology-detects-breast-cancer-relapse-up-to-68-months-before-clinical-symptoms 2025-06-20T08:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/6a63138a33e2c5b4/xjtlu-scientists-develop-ultra-stable-nanoparticles-with-40-drug-loading-capacity-for-enhanced-cancer-treatment 2025-06-20T05:03:11+00:00 hourly 0.9 https://trial.medpath.com/news/98319161eca29a2c/bmj-investigation-uncovers-data-integrity-issues-in-astrazeneca-s-ticagrelor-heart-drug-trials 2025-06-20T05:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/86f86df9c4cb849f/hkbu-researchers-engineer-exosomes-to-deliver-alzheimer-s-drug-across-blood-brain-barrier 2025-06-20T04:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/30fd0812d133944b/cube-click-secures-fda-approval-for-smile-dx-ai-powered-dental-diagnostic-platform 2025-06-20T03:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/b8b3f838d84bf74b/chemotherapy-free-regimens-and-car-t-therapies-transform-b-cell-malignancy-treatment-paradigms 2025-06-20T03:08:40+00:00 hourly 0.9 https://trial.medpath.com/news/6e168b911dfa95e9/expert-panel-identifies-key-patient-factors-for-optimizing-immunotherapy-selection-in-pd-l1-negative-nsclc 2025-06-20T03:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/7461819b1fea22ca/atezolizumab-shows-consistent-efficacy-in-cervical-cancer-regardless-of-pd-l1-status-beatcc-trial-analysis-reveals 2025-06-20T02:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/b562ae6b58dced58/abbvie-secures-2-billion-option-deal-for-gilgamesh-s-next-generation-psychedelic-therapies 2025-06-20T01:40:54+00:00 hourly 0.9 https://trial.medpath.com/news/53264f56ce18ce49/university-of-wisconsin-researchers-develop-personalized-cancer-vaccines-using-pyroptotic-vesicles-to-prevent-tumor-recurrence 2025-06-20T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/e5560c8b0c6963a1/dupilumab-treatment-for-atopic-dermatitis-linked-to-increased-psoriasis-risk-in-large-scale-study 2025-06-20T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/e40886b550bd40e1/grifols-fibrinogen-concentrate-bt524-demonstrates-non-inferiority-in-phase-iii-trial-for-surgical-bleeding 2025-06-20T00:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/1b74ad98dcd1c5f7/dgenthera-and-nusano-partner-to-scale-astatine-211-production-for-next-generation-cancer-therapy 2025-06-20T00:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/67896c592c297b35/historical-challenges-in-nf1-associated-plexiform-neurofibroma-treatment-drive-development-of-targeted-therapies 2025-06-20T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/cec24ec95a10b13d/dendritic-cell-therapy-shows-significant-survival-benefit-for-recurrent-glioblastoma-patients 2025-06-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f61ad55f29e5a167/prothena-cuts-63-of-workforce-as-company-restructures-operations-amid-pipeline-milestones 2025-06-19T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/1c1cefe64d048490/cd5-targeted-therapies-show-promise-across-cancer-autoimmunity-and-transplantation-with-first-commercial-launch-expected-by-2030 2025-06-19T21:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/f3659e493fb6f0d1/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-iii-essential-thrombocythemia-trial 2025-06-19T21:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/316b15d3e34a5558/zilia-ocular-receives-world-first-health-canada-approval-for-non-invasive-retinal-oxygen-measurement 2025-06-19T20:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/894fc0f44cd1e292/cns-oligonucleotide-licensing-deals-surge-339-to-2-81-billion-in-2024 2025-06-19T20:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/c4f18b4baacfa32b/beta-bionics-partners-with-abbott-to-integrate-ilet-bionic-pancreas-with-future-dual-glucose-ketone-sensor 2025-06-19T18:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/27e964f5606b9c6c/subcutaneous-immunoglobulin-with-hyaluronidase-shows-promise-for-idiopathic-inflammatory-myositis-treatment 2025-06-19T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/b834db83be13bf30/theranica-s-nerivio-ren-wearable-shows-sustained-migraine-efficacy-over-three-years-in-real-world-studies 2025-06-19T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/e991ef5c3bb25279/tocilizumab-biosimilar-ct-p47-demonstrates-long-term-efficacy-and-safety-in-rheumatoid-arthritis-treatment 2025-06-19T17:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/4a9d2d12895d3ae4/fda-approves-first-treatment-for-alkaptonuria-nitisinone-shows-clinical-benefits-in-rare-metabolic-disorder 2025-06-19T17:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/f679c9c5f6fa2f91/excellthera-s-zemcelpro-receives-positive-chmp-opinion-for-blood-cancer-patients-without-suitable-donors 2025-06-19T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/e55952f9ea8026fe/gene-therapy-analytics-summits-address-critical-quality-control-challenges-amid-regulatory-setbacks 2025-06-19T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/020179c25c53a3a1/glp-1-receptor-agonists-linked-to-increased-risk-of-gallbladder-disease-in-large-scale-safety-analysis 2025-06-19T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/c97ac76b827d1156/brenus-pharma-and-insphero-develop-advanced-3d-tumor-models-for-colorectal-cancer-immunotherapy-testing 2025-06-19T15:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/37452d45215aafbb/bionova-scientific-expands-into-advanced-therapies-with-third-flexfactory-platform-installation 2025-06-19T15:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/eadb10e0b771f12a/biomea-fusion-s-bmf-650-demonstrates-significant-weight-loss-in-primate-study-advancing-toward-clinical-trials 2025-06-19T13:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/e583a489ed91036c/pleopharma-s-pp-01-shows-significant-efficacy-in-phase-2b-trial-for-cannabis-withdrawal-syndrome 2025-06-19T13:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/cfdd4af67f20aed5/u-s-pharmacopeia-recognizes-mass-photometry-as-key-method-for-aav-gene-therapy-quality-standards 2025-06-19T13:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/2939a2d93a3f08b9/kras-g12c-nsclc-patients-face-limited-cns-treatment-options-despite-40-brain-metastases-rate 2025-06-19T13:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/dd42579f21bf7056/memo-therapeutics-to-present-phase-ii-results-for-first-in-class-bk-polyomavirus-treatment-at-world-transplant-congress 2025-06-19T12:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/8dc8b5775e384bc5/doe-supplies-accelerator-produced-actinium-225-for-first-ever-u-s-cancer-therapy-clinical-trial 2025-06-19T11:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/c47eef17b98e828b/synfini-and-o2nix-bio-partner-to-develop-ai-driven-cancer-metastasis-therapies-targeting-ftsj1 2025-06-19T09:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/d1162ed6e853282c/fda-cancels-advisory-committee-meeting-for-capricor-s-duchenne-therapy-amid-leadership-shake-up 2025-06-19T09:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/e43307460b11b9b8/medhub-ai-receives-pmda-approval-for-ai-powered-coronary-assessment-technology-in-japan 2025-06-19T09:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/f0c36c59588b1c27/tgs-and-viridien-launch-laconia-phase-iii-ocean-bottom-node-survey-in-gulf-of-america 2025-06-19T08:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/1190b758725646c8/hotspot-therapeutics-to-present-irf5-small-molecule-inhibitor-data-at-focis-2025 2025-06-19T07:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/5355dc16d5dd2270/simcere-zaiming-initiates-us-phase-1-trial-of-trispecific-antibody-sim0500-for-relapsed-refractory-multiple-myeloma 2025-06-19T05:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/42fbd60d00b38b3f/saptalis-pharmaceuticals-launches-fluoxetine-oral-solution-for-multiple-mental-health-conditions 2025-06-19T05:03:01+00:00 hourly 0.9 https://trial.medpath.com/news/b05eb2c6e71ad108/precision-medicine-oncology-pharmacists-emerge-as-critical-players-in-personalized-cancer-care 2025-06-19T03:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/8da50431f35280c0/insulet-presents-real-world-evidence-of-omnipod-5-benefits-in-type-2-diabetes-at-ada-2025 2025-06-19T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/92dec12ee5fe2c87/biontech-shuts-down-maryland-cell-therapy-manufacturing-following-car-t-trial-failure 2025-06-19T01:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/2617571f3026a2e1/fda-issues-critical-safety-warning-for-scopolamine-patch-following-13-global-hyperthermia-cases 2025-06-19T01:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/73a8d67f3f1fd0f4/kindeva-partners-with-rocket-science-health-to-advance-novel-intranasal-cns-drug-delivery-platform 2025-06-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/f814b318e1bdf3c6/fda-halts-clinical-trials-sending-american-cells-to-foreign-labs-for-genetic-engineering 2025-06-19T00:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ee159d9503ff3e9/ai-model-reveals-46-cognitive-decline-reduction-in-alzheimer-s-trial-reanalysis 2025-06-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/34b83aa06292365c/genecentric-secures-8m-series-c-to-commercialize-rna-based-liquid-biopsy-platform 2025-06-18T22:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/a96cf5d4bf12cf7f/avalo-therapeutics-appoints-rita-jain-to-board-as-avtx-009-phase-2-trial-for-hidradenitis-suppurativa-progresses 2025-06-18T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/e102d83070421469/kaiser-permanente-launches-fda-approved-gene-therapy-program-for-pediatric-sickle-cell-disease 2025-06-18T21:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/5254213d266b4a08/fda-approves-tafasitamab-triple-combination-for-relapsed-refractory-follicular-lymphoma 2025-06-18T21:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/d9ba52ef31fa526f/eccogene-initiates-phase-1b-trial-of-novel-oral-glp-1-receptor-agonist-azd5004-ecc5004-in-china 2025-06-18T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/be51cbdeefa97383/dapagliflozin-combination-therapy-shows-promise-for-adolescents-with-type-1-diabetes-in-clinical-trial 2025-06-18T20:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/ab609472e7c2d1a6/johnson-johnson-expands-tecnis-odyssey-iol-to-europe-middle-east-and-canada-following-us-success 2025-06-18T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/a80ae497760fa328/camurus-cam2029-shows-significant-liver-volume-reduction-in-phase-2b-trial-for-rare-polycystic-liver-disease 2025-06-18T20:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/2e9ff51e2157bc21/tolremo-therapeutics-strengthens-leadership-with-key-appointments-as-tt125-802-shows-clinical-promise 2025-06-18T19:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/7a2cd6ad2ec79b24/brightspring-s-onco360-pharmacy-selected-as-national-partner-for-three-new-cancer-and-rare-disease-therapies 2025-06-18T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/809c93a962418ced/abbvie-s-qulipta-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-head-to-head-migraine-prevention-trial 2025-06-18T18:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/12276de4fc72c8a9/singlera-genomics-gutseer-assay-achieves-81-5-sensitivity-in-detecting-early-stage-gastrointestinal-cancers 2025-06-18T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/69a69446d897a61f/abbott-partners-with-msd-to-expand-distribution-of-diabetes-drug-portfolio-in-india 2025-06-18T16:58:10+00:00 hourly 0.9 https://trial.medpath.com/news/5fc5f4d62c130f92/nervgen-appoints-randall-kaye-as-chief-medical-advisor-following-positive-spinal-cord-injury-trial-results 2025-06-18T16:57:38+00:00 hourly 0.9 https://trial.medpath.com/news/f0bda0ff116e6de1/curasight-advances-utreat-brain-cancer-therapy-with-phase-1-trial-submission-to-ema 2025-06-18T16:55:57+00:00 hourly 0.9 https://trial.medpath.com/news/ab4b374f6d072535/akari-therapeutics-secures-india-patent-for-novel-spliceosome-inhibiting-adc-payload-technology 2025-06-18T16:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/6535173f8d6d7631/respiratorius-secures-fda-pre-ind-meeting-for-val001-cancer-treatment-following-positive-physician-survey 2025-06-18T16:55:44+00:00 hourly 0.9 https://trial.medpath.com/news/4e63f598fc1b80a4/infinity-bio-secures-8m-series-a-to-advance-antibody-reactome-profiling-technology 2025-06-18T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/a3e56c9b704d26a4/climb-bio-strengthens-leadership-team-with-key-executive-appointments-to-advance-immune-mediated-disease-pipeline 2025-06-18T16:55:21+00:00 hourly 0.9 https://trial.medpath.com/news/d2317233ed94838b/pattern-computer-advances-ai-discovered-drug-for-multiple-hard-to-treat-cancers-to-testing-phase 2025-06-18T16:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/cc8eced950b6f26f/fareva-opens-new-gmp-sterile-pilot-unit-in-france-to-support-biotech-drug-manufacturing 2025-06-18T16:46:20+00:00 hourly 0.9 https://trial.medpath.com/news/c6aa9eb0841efdee/sandboxaq-releases-5-2-million-synthetic-molecules-dataset-to-accelerate-ai-driven-drug-discovery 2025-06-18T16:46:08+00:00 hourly 0.9 https://trial.medpath.com/news/5c0e1fe3edbcd94c/new-zealand-approves-over-the-counter-melatonin-and-prescription-psilocybin-for-treatment-resistant-depression 2025-06-18T16:44:47+00:00 hourly 0.9 https://trial.medpath.com/news/d0453e4756ab4c70/bavarian-nordic-sells-priority-review-voucher-for-160-million-following-chikungunya-vaccine-approval 2025-06-18T16:44:40+00:00 hourly 0.9 https://trial.medpath.com/news/fc08e211a338ddf3/aethlon-medical-advances-hemopurifier-cancer-trial-with-second-patient-treatment-in-australia 2025-06-18T16:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/62fd274f908ec85a/diagonal-therapeutics-diag723-shows-disease-modifying-potential-for-hereditary-hemorrhagic-telangiectasia-in-preclinical-studies 2025-06-18T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/af2cbbd2ba0c9974/fda-approves-expanded-pediatric-trial-for-moleculin-s-annamycin-in-acute-myeloid-leukemia 2025-06-18T16:41:18+00:00 hourly 0.9 https://trial.medpath.com/news/ab799d614c794dee/fda-approves-first-integrated-sacral-neuromodulation-system-for-urinary-urge-incontinence 2025-06-18T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/5526b88ef55932c4/health-canada-approves-expanded-dosing-and-pediatric-indication-for-firdapse-in-lambert-eaton-myasthenic-syndrome 2025-06-18T16:41:04+00:00 hourly 0.9 https://trial.medpath.com/news/a7b7e825a658ad98/md-anderson-study-identifies-three-b-cell-lymphoma-subgroups-with-distinct-cd19-car-t-response-patterns 2025-06-18T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/fee91c383034fb81/regeltec-initiates-u-s-pivotal-trial-for-hydrafil-system-in-chronic-low-back-pain-treatment 2025-06-18T16:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/c4f9d6235ac14765/biogen-launches-phase-3-pediatric-trial-of-omaveloxolone-for-friedreich-ataxia 2025-06-18T15:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/091136bc497d674e/scholar-rock-s-apitegromab-preserves-lean-muscle-mass-during-weight-loss-with-tirzepatide-in-phase-2-trial 2025-06-18T12:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/e645b6c53f521c96/actio-biosciences-raises-66m-series-b-to-advance-rare-disease-programs-targeting-ion-channel-disorders 2025-06-18T12:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/e473383579bddcdb/aligos-therapeutics-strengthens-cmc-leadership-with-industry-veteran-ahead-of-phase-2-trial 2025-06-18T12:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/9d3d09e18e9fc960/abbvie-s-atogepant-demonstrates-superior-tolerability-and-efficacy-over-topiramate-in-phase-3-migraine-prevention-trial 2025-06-18T12:49:09+00:00 hourly 0.9 https://trial.medpath.com/news/d106adb0a72789a2/draig-therapeutics-emerges-from-stealth-with-140m-to-advance-novel-neuropsychiatric-therapies 2025-06-18T12:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/d056def82543fda4/sk-biopharmaceuticals-partners-with-phnyx-lab-to-deploy-ai-powered-drug-development-platform 2025-06-18T11:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/a098b24eb38089f5/senate-republicans-drop-orphan-drug-exemptions-from-trump-tax-bill-dealing-blow-to-rare-disease-drug-development 2025-06-18T09:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/3444b9bf025b8142/sanofi-s-tzield-debuts-in-china-as-first-fda-approved-therapy-to-delay-type-1-diabetes-onset 2025-06-18T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/d3a8460bc453a12b/inoviq-s-car-exosome-therapy-achieves-88-cancer-cell-kill-rate-in-preclinical-study 2025-06-18T09:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/16ae6b028bf06080/mercalis-and-pharmacord-merge-to-form-valeris-creating-integrated-therapy-commercialization-platform 2025-06-18T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/162aeec6116433bf/novartis-and-msn-settle-entresto-patent-dispute-boosting-divi-s-laboratories-outlook 2025-06-18T09:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/4f7e4cdaede72d7f/fda-approves-first-simultaneous-whole-exome-and-transcriptome-cancer-test-for-precision-oncology 2025-06-18T09:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/591525b57cfc636e/nec-and-chugai-pharmaceutical-develop-ai-system-to-accelerate-cancer-drug-combination-discovery 2025-06-18T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/9b577871c53bfd46/expanding-innovations-receives-fda-clearance-for-n-gage-lumbar-plate-system 2025-06-18T08:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/c3cb844f6197cd5b/applied-dna-sciences-announces-leadership-transition-as-ceo-dr-james-hayward-retires-after-20-year-tenure 2025-06-18T06:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/402dfbc4ed2045e6/glenmark-pharma-receives-five-fda-observations-at-north-carolina-facility-no-data-integrity-issues-found 2025-06-18T06:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/9e44aa27b3ac4517/saverone-receives-us-patent-for-advanced-sensor-fusion-technology-to-combat-driver-distraction 2025-06-18T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/a23a38b43099bb82/blue-biofuels-secures-seventh-u-s-patent-for-cellulose-to-sugar-technology 2025-06-18T05:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/a3922c34aceeb6a3/medibank-partners-with-emyria-to-fund-innovative-ptsd-treatment-program-in-australian-healthcare-first 2025-06-18T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/c24ac15cfa7db830/occam-immune-and-cancer-research-institute-form-strategic-partnership-to-advance-personalized-immunotherapy 2025-06-18T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/6b12bee1d81ad9db/sartorius-stedim-biotech-completes-major-manufacturing-expansion-in-france-to-meet-growing-bioprocessing-demand 2025-06-18T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/48c4aa40ef193cd2/relmada-therapeutics-strengthens-ndv-01-bladder-cancer-program-with-key-leadership-appointments-ahead-of-phase-3-trial 2025-06-18T02:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/6e40e041ed93c59e/castle-biosciences-and-scibase-partner-to-develop-ai-powered-atopic-dermatitis-flare-prediction-test 2025-06-18T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/fa383c62c5a981cc/medtech-products-recalls-little-remedies-honey-cough-syrup-nationwide-due-to-bacterial-contamination 2025-06-18T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/28cbb0d4291c6703/city-of-hope-receives-23-7-million-arpa-h-grant-to-map-immunotherapy-resistance-in-lung-cancer 2025-06-18T00:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/a0cf632fb376d73c/incannex-healthcare-forms-joint-venture-with-mind-medicine-australia-to-launch-psychedelic-therapy-clinic-in-melbourne 2025-06-18T00:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/b745fe5d4ca36d80/nmdp-access-trial-shows-mismatched-donors-expand-stem-cell-transplant-access-for-blood-cancer-patients 2025-06-18T00:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/7c190e31416e1a19/lung-cancer-research-foundation-and-boehringer-ingelheim-launch-2-25-million-initiative-to-target-her2-mutant-lung-cancer 2025-06-18T00:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/a2f16b5d8423ea8d/iovance-cfo-resigns-amid-amtagvi-launch-struggles-and-securities-fraud-investigation 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3be6a5004c85519c/earlyhealth-group-acquires-turkish-pharmaceutical-distributor-corena-in-100m-life-sciences-expansion 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7afe1b47d645c91/novel-mitochondrial-biomarkers-identified-for-atrial-fibrillation-through-integrated-bioinformatics-analysis 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f86d6dc3874401b8/microbot-medical-secures-china-patent-for-liberty-robotic-system-ahead-of-q3-2025-us-launch 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fd0c2f63551e59c7/three-minute-eeg-test-shows-promise-for-early-alzheimer-s-detection-in-clinical-trial 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/26350a60dd30bcc7/tislelizumab-shows-promise-as-adjuvant-therapy-for-high-risk-hepatocellular-carcinoma-patients 2025-06-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/55ad7075eb25a9a9/university-of-georgia-develops-first-broad-spectrum-fungal-vaccine-enters-clinical-trials 2025-06-17T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/a9ac34d30bcff351/canada-outpaces-oecd-countries-in-new-medicine-launches-despite-rising-treatment-costs 2025-06-17T21:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/8b14a7e980477dda/bioaegis-therapeutics-receives-fda-fast-track-designation-for-novel-ards-treatment 2025-06-17T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/0cd1245fdf66f850/exceptional-responders-14-pancreatic-cancer-patients-show-remarkable-immunotherapy-outcomes-in-multi-institutional-study 2025-06-17T21:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/8504085bdb17abab/celltrio-secures-15-million-to-accelerate-global-expansion-of-cell-therapy-automation-platform 2025-06-17T21:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/61cb881e6696375b/bioage-labs-partners-with-norwegian-biobank-to-accelerate-aging-related-drug-discovery 2025-06-17T21:01:25+00:00 hourly 0.9 https://trial.medpath.com/news/63d08456c3f65080/skyhawk-therapeutics-initiates-phase-2-3-trial-of-sky-0515-for-huntington-s-disease 2025-06-17T20:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/5783de34ddb28550/ashvattha-therapeutics-unveils-novel-nanomedicine-radiotracers-for-neuroinflammation-and-cancer-imaging-at-snmmi-2025 2025-06-17T20:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/67ef0a85c23bc83f/visby-medical-secures-65-million-to-launch-fda-authorized-at-home-sti-test 2025-06-17T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/1648a1badc323c8f/pelage-pharmaceuticals-pp405-shows-hair-regeneration-potential-in-phase-2a-trial 2025-06-17T20:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/9e1052fb89f55d02/clinical-trial-launches-in-florida-to-test-investigational-oral-medication-for-severe-thunderstorm-aversion-in-dogs 2025-06-17T19:11:09+00:00 hourly 0.9 https://trial.medpath.com/news/c206e461c29a081a/quilt-health-secures-6m-seed-funding-to-modernize-clinical-trial-access-for-complex-diseases 2025-06-17T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/d587f673c2c4f6c3/nature-study-validates-non-invasive-fat-reduction-technology-for-abdominal-obesity-treatment 2025-06-17T18:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/93911731d6c976a2/maxion-therapeutics-strengthens-leadership-with-appointment-of-dr-stefan-hartle-as-chief-development-officer 2025-06-17T18:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/37a361d28bfe8e7d/heart-drug-cilostazol-shows-promise-for-treating-growth-disorders-in-preclinical-study 2025-06-17T18:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/8d70dbda58321064/mark-cuban-cost-plus-drug-company-expands-affordable-healthcare-access-through-strategic-partnerships 2025-06-17T16:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/243dab8fb1532c59/uk-regulator-reports-111-deaths-potentially-linked-to-glp-1-weight-loss-medications 2025-06-17T16:56:27+00:00 hourly 0.9 https://trial.medpath.com/news/419dc2e233102445/avata-biosciences-secures-95m-partnership-with-oceanus-bio-for-novel-cbd-therapies-in-asian-markets 2025-06-17T16:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/6ccea7424f2e6c7b/aragen-to-launch-gmp-biologics-manufacturing-in-india-with-advanced-fed-batch-platform 2025-06-17T16:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/1f314f77b810ab38/llusern-scientific-achieves-iso-13485-certification-for-rapid-uti-diagnostic-system 2025-06-17T16:55:24+00:00 hourly 0.9 https://trial.medpath.com/news/c8a65f6f0223fc5d/sunrock-biopharma-and-escugen-partner-to-develop-first-in-class-ccr9-targeted-adc-for-solid-tumors 2025-06-17T16:51:34+00:00 hourly 0.9 https://trial.medpath.com/news/e21b20395626cd91/agenus-partners-with-noetik-to-develop-ai-powered-biomarkers-for-precision-immunotherapy 2025-06-17T16:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/4fdacb07cf745ef9/hanchorbio-s-hcb101-checkpoint-inhibitor-shows-promising-safety-and-efficacy-balance-in-phase-1b-trial 2025-06-17T16:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/3a908af60d734f34/processa-pharmaceuticals-secures-452-5m-licensing-deal-for-gastroparesis-drug-pcs12852 2025-06-17T16:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/0ceb72c802872d6c/fda-grants-orphan-drug-designation-to-medicovestor-s-first-in-class-adc-for-pancreatic-cancer 2025-06-17T16:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/11a338ababbc9ccb/astrocyte-pharmaceuticals-initiates-phase-2-trial-for-first-in-class-concussion-drug-ast-004 2025-06-17T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/570391531b522af6/tharimmune-appoints-new-ceo-and-board-members-to-advance-opioid-antagonist-th104-development 2025-06-17T16:19:43+00:00 hourly 0.9 https://trial.medpath.com/news/74a388c6f4f8f78f/lipella-pharmaceuticals-secures-patent-for-mri-based-diagnostic-technology-to-detect-interstitial-cystitis 2025-06-17T16:18:58+00:00 hourly 0.9 https://trial.medpath.com/news/a7166a8e3398e713/health-canada-proposes-elimination-of-phase-iii-clinical-trials-for-biosimilar-approvals 2025-06-17T16:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/56f896f90ec72860/phoenix-study-launches-world-s-largest-pharmacogenomics-trial-to-personalize-drug-prescribing-in-scotland 2025-06-17T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/65b38033620c6e8d/taiwan-s-jyong-biotech-raises-20m-in-nasdaq-ipo-to-advance-botanical-urinary-disease-treatments 2025-06-17T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/8ecea3a335aa0428/china-proposes-30-day-review-pathway-for-innovative-drug-clinical-trials-nationwide 2025-06-17T14:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/da19f37a4e683912/prometheus-laboratories-expands-precision-guided-dosing-platform-with-new-tests-for-ibd-biologics 2025-06-17T14:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/236272e81bbe0dd5/foresee-pharmaceuticals-completes-enrollment-in-phase-3-trial-for-central-precocious-puberty-treatment 2025-06-17T13:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/0ef41ccd7a1f2672/tisento-therapeutics-receives-fda-fast-track-designation-for-zagociguat-in-melas-treatment 2025-06-17T13:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/3ffca2603813b6f0/qureight-s-ai-powered-synthetic-control-arms-validate-efficacy-of-avalyn-s-inhaled-pirfenidone-for-rare-lung-disease 2025-06-17T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/56dc77feb3529c4c/formycon-launches-eur50-million-corporate-bond-to-accelerate-biosimilar-portfolio-development 2025-06-17T13:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/ae03b3b781730ecb/basf-opens-new-gmp-solution-center-in-michigan-to-strengthen-biopharma-manufacturing-capabilities 2025-06-17T13:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/077c8cac5b69919f/isomorphic-labs-appoints-dr-ben-wolf-as-chief-medical-officer-establishes-us-operations 2025-06-17T12:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/f5b8899f1c614b89/ucsf-researchers-develop-car-t-therapy-for-aggressive-bladder-cancer-variant-using-novel-biomarkers 2025-06-17T12:06:42+00:00 hourly 0.9 https://trial.medpath.com/news/028af0dc1ba48cec/alzheimer-s-and-parkinson-s-charities-launch-drug-repurposing-partnership-to-accelerate-treatment-development 2025-06-17T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/c70c36e5c2d3af5a/vsa-announces-acquisition-of-ai-clinical-development-company-hopeai-to-transform-drug-development-timelines 2025-06-17T12:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/ab230db01ac33d14/nodthera-appoints-former-astrazeneca-executive-elisabeth-bjork-to-board-as-phase-2-obesity-trial-advances 2025-06-17T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/32992eb03acc8e7d/eli-lilly-acquires-gene-editing-biotech-verve-therapeutics-for-1-3-billion-to-expand-cholesterol-treatment-pipeline 2025-06-17T10:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/a2818ccfd7e0b1d8/china-patent-office-upholds-harbour-biomed-s-heavy-chain-antibody-patent-in-legal-victory-over-biocytogen 2025-06-17T10:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/b24e7bdab37dcde3/angle-advances-liquid-biopsy-technology-with-dual-dna-analysis-and-androgen-receptor-profiling-at-eacr-2025 2025-06-17T10:58:21+00:00 hourly 0.9 https://trial.medpath.com/news/2133288f097d59ef/orion-and-glykos-extend-adc-partnership-to-develop-six-next-generation-cancer-therapies 2025-06-17T09:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/079b341381515037/simvastatin-fails-to-show-antidepressant-benefits-in-major-depression-and-obesity-trial 2025-06-17T09:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/785f4468cb32f1b7/china-s-nmpa-proposes-streamlined-30-day-review-channel-for-category-1-innovative-drugs 2025-06-17T09:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/c0e438e1bc00aadc/hera-biotech-acquires-herafem-point-of-care-cervical-cancer-diagnostic-with-91-sensitivity 2025-06-17T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0fedfe0b5047cf5/smartlabs-and-iwg-form-10-year-partnership-to-expand-global-lab-infrastructure-access 2025-06-17T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0333f684866fda3d/everzom-secures-eur3-million-france-2030-funding-to-scale-exosome-bioproduction-for-crohn-s-disease-treatment 2025-06-17T05:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/a73fe68680eea2a5/beyond-air-submits-fda-application-for-next-generation-lungfit-ph-ii-nitric-oxide-system 2025-06-17T05:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/04e9159f88a49c62/clarity-pharmaceuticals-secures-major-manufacturing-deal-to-scale-cu-sar-bispsma-production-for-prostate-cancer-diagnostics 2025-06-17T05:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/4ca0965271137af9/biomx-achieves-breakthrough-in-phage-therapy-with-positive-phase-2-results-for-antibiotic-resistant-infections 2025-06-17T05:00:43+00:00 hourly 0.9 https://trial.medpath.com/news/0aa4caa63a6ebb6c/health-canada-approves-abbott-s-rapid-whole-blood-test-for-concussion-assessment 2025-06-17T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a00068f1f3f0a9e5/clinical-trial-activity-plummets-20-as-funding-crisis-grips-biotech-sector 2025-06-17T03:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/525242f417a868b9/thyroid-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-06-17T02:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/51d65171a7c3e52b/purdue-pharma-secures-7-4-billion-opioid-settlement-support-from-55-states-and-territories 2025-06-17T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/ee8b47e615772394/fda-approves-csl-s-andembry-for-hereditary-angioedema-prevention-with-novel-factor-xiia-targeting 2025-06-17T01:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/def7ae8c204f3426/blood-test-detects-early-liver-transplant-rejection-using-cell-free-dna-analysis 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/9c679b2bbe01309d/trust-trial-shows-primary-surgery-improves-progression-free-survival-in-advanced-ovarian-cancer-despite-missing-overall-survival-endpoint 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0bbb081182c3e71/fda-issues-second-complete-response-letter-for-odronextamab-in-relapsed-refractory-follicular-lymphoma 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b44645a801669dc/biogen-s-leqembi-shows-accelerating-growth-with-58-global-sales-increase-despite-slow-market-adoption 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/b7167d38a72b4c1a/digital-inhaler-technology-shows-promise-for-early-copd-exacerbation-detection 2025-06-17T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/22dfe8c6abbf0412/mabion-and-novalgen-partner-to-advance-novel-t-cell-engager-nvg-222-for-cancer-treatment 2025-06-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/17b6742d49cfb738/enzene-expands-new-jersey-biomanufacturing-facility-by-26000-square-feet-ahead-of-opening 2025-06-16T23:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/c617c985bb0b7577/edx-medical-partners-with-spire-healthcare-to-advance-diagnostic-innovation-for-cancer-and-cardiovascular-disease 2025-06-16T23:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/815586c4d9ec5b9f/help-therapeutics-partners-with-china-resources-sanjiu-to-advance-ipsc-derived-heart-failure-therapy-hicm-188 2025-06-16T23:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/52ce3449cede8a04/cresilon-expands-vetigel-distribution-to-canadian-veterinary-market-through-mccarthy-vet-partnership 2025-06-16T22:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/160c36fe37c41004/lantern-pharma-reports-complete-response-in-advanced-nsclc-patient-after-failed-standard-therapies 2025-06-16T22:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/8f0b537ecf25a90b/shasqi-achieves-first-in-human-success-with-click-chemistry-cancer-therapy-delivering-12-fold-higher-doxorubicin-doses 2025-06-16T21:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/c02403cc2a5fa698/geovax-receives-ema-approval-to-skip-phase-1-2-trials-for-mpox-vaccine-accelerating-path-to-market 2025-06-16T21:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/a5128a26d9e4d904/astrazeneca-s-surovatamig-shows-promise-as-next-generation-bite-therapy-for-relapsed-refractory-b-all 2025-06-16T21:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/19268714818eb17c/patent-extensions-drive-200-billion-in-excess-u-s-drug-spending-i-mak-analysis-reveals 2025-06-16T21:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/5ad8f2398f495698/clarametyx-s-cmtx-101-shows-promise-in-cystic-fibrosis-infection-trial-advances-to-next-phase 2025-06-16T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/dc99ab74f480c9d9/eolo-pharma-s-sana-demonstrates-novel-energy-burning-mechanism-for-obesity-treatment-in-first-in-human-study 2025-06-16T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/cb79ee3f3b9f1b0d/integrated-cdmo-cro-services-can-reduce-drug-development-timelines-by-nearly-three-years-tufts-study-finds 2025-06-16T21:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/21c97c885779faad/asc2escalate-trial-shows-promising-results-for-asciminib-in-second-line-cml-treatment 2025-06-16T20:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/ae2bc35953509ace/personalized-mrna-cancer-vaccine-shows-promise-in-groundbreaking-bowel-cancer-trial 2025-06-16T19:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/ad0c1e2d55987d34/supernus-pharmaceuticals-acquires-sage-therapeutics-for-795-million-strengthening-neuropsychiatry-portfolio 2025-06-16T18:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/10b401f49b90aa45/solu-therapeutics-appoints-enda-moran-as-coo-to-scale-cytac-platform-operations 2025-06-16T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/423ddb2040cd29eb/supernus-pharmaceuticals-acquires-sage-therapeutics-for-up-to-795-million-securing-postpartum-depression-drug-zurzuvae 2025-06-16T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/02285237588f5e5c/liso-cel-achieves-95-5-response-rate-in-relapsed-refractory-marginal-zone-lymphoma 2025-06-16T17:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/9376c80c601708a6/single-psilocybin-dose-provides-two-year-depression-relief-in-cancer-patients 2025-06-16T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/0d6003b8f6b40643/virogates-and-genspeed-achieve-breakthrough-in-point-of-care-chronic-inflammation-testing-for-longevity-market 2025-06-16T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/94f5ddce4c091c4c/mbx-biosciences-submits-ind-application-for-once-monthly-obesity-drug-mbx-4291 2025-06-16T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/a2e6b94521cbcb41/novo-nordisk-loses-canadian-semaglutide-patent-protection-over-missed-450-fee-opening-door-to-generics-in-2026 2025-06-16T17:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/085c8bd3ef7858fb/bdd-pharma-s-oralogik-system-advances-timed-release-drug-delivery-for-adhd-and-rheumatoid-arthritis 2025-06-16T17:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/070095c8b9b7e0a8/first-patient-treated-with-novel-b-cell-targeting-therapy-for-myasthenia-gravis-in-phase-iii-trial 2025-06-16T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/f180a2faa1a2f02b/alzamend-neuro-completes-5-million-financing-to-advance-five-phase-ii-trials-for-al001-lithium-therapy 2025-06-16T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/a9766cc1a818ed5d/zircon-phase-3-trial-demonstrates-high-accuracy-of-novel-pet-tracer-for-kidney-cancer-detection 2025-06-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/9942eba7d04bbe64/cdc-sponsors-first-clinical-trial-of-needle-free-rotavirus-vaccine-using-dissolvable-microarray-patch-technology 2025-06-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/d402fbfb481dc5c9/teva-and-fosun-pharma-form-strategic-partnership-for-novel-anti-pd1-il2-cancer-immunotherapy-tev-56278 2025-06-16T16:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/bcde49fd6b1b8418/debiopharm-initiates-first-in-human-trial-of-cd37-targeted-adc-debio-1562m-for-relapsed-refractory-aml 2025-06-16T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/c687a1494dbbf5f8/abbvie-s-verona-trial-for-high-risk-myelodysplastic-syndrome-fails-to-meet-primary-survival-endpoint 2025-06-16T16:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/26423a9569551f75/penumbra-completes-enrollment-in-landmark-storm-pe-trial-testing-thrombectomy-for-pulmonary-embolism 2025-06-16T16:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/a55824a1728f0445/innovative-molecules-completes-phase-1b-enrollment-for-novel-hsv-inhibitor-im-250 2025-06-16T16:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/763aa3d18545d2d2/xlife-sciences-expands-asian-footprint-through-strategic-partnerships-in-digital-health-and-precision-oncology 2025-06-16T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a35e3d067711e594/neurizon-s-nuz-001-demonstrates-neuroprotective-effects-in-huntington-s-disease-zebrafish-model 2025-06-16T15:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/b2c2a33e5c2d9572/ubrigene-launches-gmp-compliant-ipsc-banks-to-accelerate-cell-therapy-development 2025-06-16T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/57940e5e9f1c62fa/quiver-bioscience-names-co-founder-graham-dempsey-ceo-to-advance-nav1-7-targeting-aso-for-chronic-pain 2025-06-16T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/c2da200d95ed8569/elite-pharmaceuticals-achieves-bioequivalence-for-generic-anticoagulant-in-27-billion-market 2025-06-16T12:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/706ebd5a75424357/d-d-pharmatech-s-dd01-shows-rapid-liver-fat-reduction-in-mash-phase-2-trial-matching-competitor-results-in-quarter-of-the-time 2025-06-16T12:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/20dad343693fba30/circle-pharma-s-cid-078-receives-fda-orphan-drug-designation-for-small-cell-lung-cancer-treatment 2025-06-16T12:51:26+00:00 hourly 0.9 https://trial.medpath.com/news/fd0e29402e4acaea/nextcure-and-simcere-zaiming-form-strategic-partnership-for-cdh6-targeting-adc-sim0505 2025-06-16T12:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/f850712eb25d8538/incyte-s-inca033989-shows-86-response-rate-in-calr-mutant-blood-cancer-trial 2025-06-16T12:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/740c7931010f2ee8/pierre-fabre-acquires-global-rights-to-next-generation-egfr-inhibitors-for-nsclc-treatment 2025-06-16T12:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/ec8650ecad7a79c4/revolutionary-blood-test-enables-celiac-disease-diagnosis-without-gluten-challenge 2025-06-16T12:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/5c6c2269ec7d6c92/bluegenes-and-levrx-partner-to-integrate-real-time-pharmacogenetic-testing-into-pharmacy-benefit-systems 2025-06-16T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/1e45393d7270a3af/onco-innovations-partners-with-university-of-alberta-to-advance-pnkp-inhibitor-research-for-glioblastoma-treatment 2025-06-16T08:49:16+00:00 hourly 0.9 https://trial.medpath.com/news/4be61e83544a3e70/varenicline-bupropion-combination-shows-promise-for-alcohol-use-disorder-treatment 2025-06-16T08:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/967f06b911fe414f/s-biomedics-reports-promising-12-month-data-for-parkinson-s-cell-therapy-a9-dpc-in-phase-1-2a-trial 2025-06-16T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/5b054dde4d550c36/tg01-cancer-vaccine-shows-promising-clinical-activity-in-ras-mutant-multiple-myeloma 2025-06-16T08:47:36+00:00 hourly 0.9 https://trial.medpath.com/news/0b0879106ac2b371/pulmovant-publishes-phase-1-data-supporting-once-daily-inhaled-mosliciguat-for-pulmonary-hypertension 2025-06-16T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/3e302d5c399c2989/klotho-neurosciences-raises-11-million-through-warrant-exercises-achieves-debt-free-status 2025-06-16T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/42c5e57c1e63443d/poltreg-establishes-u-s-subsidiary-immuthera-and-receives-positive-ema-opinion-for-type-1-diabetes-cell-therapy 2025-06-16T06:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/b30061887c327f0b/olverembatinib-shows-promising-results-in-multiple-philadelphia-chromosome-positive-all-studies 2025-06-16T05:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/63ca7288125b9ef9/uk-flair-trial-demonstrates-superior-outcomes-with-chemotherapy-free-combination-therapy-for-chronic-lymphocytic-leukaemia 2025-06-16T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/aa227ac6fe7453cb/adolore-biotherapeutics-reports-positive-preclinical-data-for-gene-therapy-targeting-chronic-knee-pain 2025-06-16T00:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/79497edf8433bbcb/samsung-biologics-expands-into-preclinical-research-with-launch-of-samsung-organoids-drug-screening-platform 2025-06-16T00:46:38+00:00 hourly 0.9 https://trial.medpath.com/news/cb1bb8ec6625c6b0/nhs-app-to-feature-clinical-trial-matching-system-as-uk-targets-150-day-setup-times 2025-06-16T00:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/e648d45ed0dee18f/axcelead-and-a2-healthcare-form-strategic-partnership-to-accelerate-drug-r-d-in-japan 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3873ff3b26df6cbb/hengrui-and-kailera-present-phase-2-data-for-dual-glp-1-gip-agonist-and-oral-glp-1-therapies-at-ada-2025 2025-06-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/17164609beec6beb/fda-formally-rescinds-laboratory-developed-test-rule-following-court-defeat 2025-06-15T21:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/d1a58e759bc2598f/novel-btk-degrader-bgb-16673-achieves-84-8-response-rate-in-heavily-pretreated-cll-sll-patients 2025-06-15T16:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/893676c39f802f1f/intellia-s-crispr-gene-therapy-shows-98-reduction-in-hae-attacks-after-three-years 2025-06-15T16:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/3e1367a2d3c4365a/adalimumab-biosimilars-show-high-acceptance-and-long-term-durability-in-ibd-patients-across-age-groups 2025-06-15T08:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/0ec00a685ddbbd91/socioeconomic-disparities-drive-worse-outcomes-in-multiple-myeloma-patients-despite-treatment-advances 2025-06-15T03:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/f768538b78eb4ead/eha-2025-showcases-breakthrough-therapies-for-hematologic-malignancies 2025-06-15T03:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/56107ceca77d5b9f/biologic-therapies-transform-respiratory-care-as-clinicians-embrace-earlier-precision-based-treatment-strategies 2025-06-15T03:02:36+00:00 hourly 0.9 https://trial.medpath.com/news/fbd29ff1d746378b/sigachi-industries-secures-environmental-approval-for-major-api-manufacturing-facility-in-andhra-pradesh 2025-06-15T01:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/5164f6064d3dafbd/syngene-international-s-bengaluru-facility-receives-clean-fda-inspection-with-nai-status 2025-06-15T01:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/6a874b4c67fe601e/twin-health-raises-53-million-to-scale-ai-powered-digital-twin-platform-for-metabolic-disease-management 2025-06-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c9e9f952e7dc8965/ethniq-launches-patented-natural-antifungal-treatment-showing-90-efficacy-in-clinical-trials 2025-06-14T23:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/95afed83c4412497/sun-pharma-names-kirti-ganorkar-as-managing-director-in-major-leadership-transition 2025-06-14T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/addf86b7859fbe40/multimodal-ai-system-demonstrates-superior-survival-prediction-for-hepatocellular-carcinoma-immunotherapy 2025-06-14T21:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/c56a041ea310849b/nice-rejects-first-alzheimer-s-disease-modifying-drugs-for-nhs-use-due-to-cost-effectiveness-concerns 2025-06-14T20:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/ec77011d7f265677/natco-pharma-s-mekaguda-api-facility-receives-fda-establishment-inspection-report-following-successful-remediation 2025-06-14T20:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/b297fb78b3cbcd2f/inspiremd-receives-fda-approval-for-cguard-prime-carotid-stent-system-with-record-low-stroke-rates 2025-06-14T18:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/cdf5cfb2ce1c885a/car-t-cell-therapies-show-promise-for-severe-autoimmune-diseases-at-eular-2025 2025-06-14T17:00:42+00:00 hourly 0.9 https://trial.medpath.com/news/322a6a5b6bb1d34a/benchling-partners-with-merck-to-streamline-vaccine-bioanalysis-through-integrated-digital-platform 2025-06-14T16:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/c6a7151631fcf64c/bristol-myers-squibb-advances-targeted-protein-degradation-platform-with-new-clinical-data-at-eha-2025 2025-06-14T12:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/ace0c6cfadd68ac3/sun-pharma-s-halol-facility-receives-eight-fda-observations-following-latest-inspection 2025-06-14T10:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6a456eda45516cf/itm-to-present-phase-3-compete-trial-data-at-snmmi-2025-meeting 2025-06-14T05:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/187f873d410a1c86/regor-therapeutics-to-present-phase-2a-data-for-oral-glp-1-agonist-rgt-075-at-ada-2025 2025-06-14T04:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/f2aac5aa0bf0660d/food-deserts-compound-clinical-trial-access-barriers-for-breast-cancer-patients 2025-06-14T03:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/088d59e09bb0a12e/fda-delays-kalvista-s-sebetralstat-approval-decision-due-to-resource-constraints 2025-06-14T02:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/596915bed3eafb03/intravenous-rehydration-shows-safety-in-severely-malnourished-children-challenging-who-guidelines 2025-06-14T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/994605963b813734/fda-delays-sebetralstat-approval-decision-for-hereditary-angioedema-treatment-due-to-resource-constraints 2025-06-14T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/d38277e86f46c3a2/olutasidenib-maintenance-therapy-demonstrates-sustained-remission-in-idh1-mutated-aml-patients 2025-06-13T23:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/04a497df8bdb3e51/thermo-fisher-scientific-explores-4-billion-diagnostics-unit-sale-to-streamline-portfolio 2025-06-13T22:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/01ac40f641a7f8f0/neuroem-therapeutics-secures-1-33-million-in-series-a-funding-to-advance-drug-free-alzheimer-s-treatment 2025-06-13T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/575287933097870c/ponatinib-shows-superior-survival-outcomes-in-ph-all-patients-with-persistent-mrd-after-induction 2025-06-13T21:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/59d2c14a851de98a/nectero-medical-secures-cpt-codes-for-investigational-aaa-treatment-as-phase-2-3-trial-shows-promise 2025-06-13T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/d682f98139871ff3/cyclophosphamide-plus-cyclosporin-emerges-as-new-standard-of-care-for-gvhd-prevention-in-blood-cancer-transplants 2025-06-13T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/540074f625793216/innocan-pharma-advances-liposomal-cbd-platform-for-chronic-pain-as-peer-reviewed-study-highlights-non-opioid-alternative 2025-06-13T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/8f150a45605ff6f3/ema-recommends-first-eu-vaccine-against-swine-dysentery-targeting-disease-with-30-50-mortality-rate 2025-06-13T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/7988131947a73564/european-commission-launches-combine-pilot-program-to-streamline-combined-medicine-and-medical-device-studies 2025-06-13T20:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/3dbf8d12398e1bb0/first-in-class-cbp-p300-inhibitor-tt125-802-shows-promise-in-treatment-resistant-nsclc 2025-06-13T19:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/88fe78b596ee87d2/ellipsis-health-raises-45m-series-a-to-launch-sage-ai-care-manager-with-emotional-intelligence 2025-06-13T19:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/657763b73271f2dc/serum-institute-of-india-partners-with-dndi-to-develop-affordable-dengue-monoclonal-antibody-treatment 2025-06-13T17:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/19526526c3398863/fapi-based-pet-imaging-shows-superior-performance-over-fdg-pet-for-gastrointestinal-cancer-detection 2025-06-13T17:12:34+00:00 hourly 0.9 https://trial.medpath.com/news/dbef3b582d8502ee/covid-19-vaccination-reduces-severe-kidney-damage-risk-in-hospitalized-patients-ucla-study-finds 2025-06-13T17:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/77f3d8bb6836a028/johnson-johnson-s-dual-targeting-car-t-therapy-achieves-80-complete-response-rate-in-lymphoma-trial 2025-06-13T17:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/ee89a424ca5d0837/nextcell-pharma-completes-patient-dosing-in-phase-ii-protrans-young-trial-for-pediatric-type-1-diabetes 2025-06-13T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/9a32dd5b38bb91a0/vial-doses-first-participants-in-phase-1-trial-of-half-life-extended-anti-tl1a-antibody-for-ibd-treatment 2025-06-13T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/1301558722d4596f/panavance-therapeutics-reports-promising-phase-1-results-for-misetionamide-in-pancreatic-cancer 2025-06-13T17:10:48+00:00 hourly 0.9 https://trial.medpath.com/news/faa56df6e11b3b6a/ucb-announces-5-billion-u-s-biologics-manufacturing-investment-to-strengthen-supply-chain 2025-06-13T17:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/85310635e4b8bd04/pegloticase-achieves-complete-gout-remission-in-43-of-patients-after-52-weeks-of-treatment 2025-06-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/95d510cf7ff10f9e/fda-places-clinical-hold-on-rocket-pharmaceuticals-gene-therapy-trial-after-patient-death 2025-06-13T16:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/2f340f951992656b/citius-pharmaceuticals-closes-15-8m-direct-offering-to-fund-lymphir-commercial-launch 2025-06-13T15:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/b12c0b76ab13bfb9/quest-diagnostics-partners-with-md-anderson-to-develop-multi-cancer-risk-blood-test-for-2026-launch 2025-06-13T14:21:00+00:00 hourly 0.9